<!DOCTYPE article PUBLIC "-//NLM//DTD JATS (Z39.96) Journal Publishing DTD v1.1 20151215//EN" "https://jats.nlm.nih.gov/publishing/1.1/JATS-journalpublishing1.dtd">
<article xmlns:xlink="http://www.w3.org/1999/xlink" specific-use="sps-1.9" dtd-version="1.1" xml:lang="pt" article-type="research-article">
  <front>
    <journal-meta>
      <journal-id journal-id-type="publisher-id">abc</journal-id>
      <journal-title-group>
        <journal-title>Arquivos Brasileiros de Cardiologia</journal-title>
        <abbrev-journal-title abbrev-type="publisher">Arq. Bras. Cardiol.</abbrev-journal-title>
      </journal-title-group>
      <issn pub-type="ppub">0066-782X</issn>
      <issn pub-type="epub">1678-4170</issn>
      <publisher>
        <publisher-name>Sociedade Brasileira de Cardiologia - SBC</publisher-name>
        <publisher-loc>S&#227;o Paulo, SP, Brazil</publisher-loc>
      </publisher>
    </journal-meta>
    <article-meta>
      <article-id pub-id-type="publisher-id" specific-use="scielo-v3">FJFHbjm7hHjNCBM4YLMbwFJ</article-id>
      <article-id pub-id-type="other">00009</article-id>
      <article-id pub-id-type="publisher-id" specific-use="scielo-v2">S0066-782X2009000200009</article-id>
      <article-id pub-id-type="publisher-id" specific-use="scielo-v1">S0066-782X(09)09200209</article-id>
      <article-id pub-id-type="doi">10.1590/S0066-782X2009000200009</article-id>
      <article-categories>
        <subj-group subj-group-type="heading">
          <subject>Artigos Originais</subject>
        </subj-group>
      </article-categories>
      <title-group>
        <article-title>Ecocardiografia e teste de caminhada de 6 minutos na disfun&#231;&#227;o sist&#243;lica do ventr&#237;culo esquerdo</article-title>
      </title-group>
      <contrib-group>
        <contrib contrib-type="author">
          <name>
            <surname>Berisha</surname>
            <given-names>Venera</given-names>
          </name>
          <xref ref-type="aff" rid="aff01"/>
        </contrib>
        <contrib contrib-type="author">
          <name>
            <surname>Bajraktari</surname>
            <given-names>Gani</given-names>
          </name>
          <xref ref-type="aff" rid="aff01"/>
        </contrib>
        <contrib contrib-type="author">
          <name>
            <surname>Dobra</surname>
            <given-names>Dritero</given-names>
          </name>
          <xref ref-type="aff" rid="aff02"/>
        </contrib>
        <contrib contrib-type="author">
          <name>
            <surname>Haliti</surname>
            <given-names>Edmond</given-names>
          </name>
          <xref ref-type="aff" rid="aff01"/>
        </contrib>
        <contrib contrib-type="author">
          <name>
            <surname>Bajrami</surname>
            <given-names>Reshat</given-names>
          </name>
          <xref ref-type="aff" rid="aff01"/>
        </contrib>
        <contrib contrib-type="author">
          <name>
            <surname>Elezi</surname>
            <given-names>Shpend</given-names>
          </name>
          <xref ref-type="aff" rid="aff02"/>
        </contrib>
      </contrib-group>
      <aff id="aff02">
        <addr-line>
          <named-content content-type="city">Prishtina</named-content>
        </addr-line>
        <institution content-type="orgname">Universidade de Prishtina</institution>
        <institution content-type="orgdiv1">Faculdade de Medicina </institution>
        <country country="">Kosovo</country>
      </aff>
      <aff id="aff01">
        <addr-line>
          <named-content content-type="city">Prishtina</named-content>
        </addr-line>
        <institution content-type="orgname">Universidade Centro Cl&#237;nico de Kosova</institution>
        <institution content-type="orgdiv1">Cl&#237;nica Geral </institution>
        <institution content-type="orgdiv2">Segunda Divis&#227;o de Cardiologia</institution>
        <country country="">Kosovo</country>
      </aff>
      <pub-date date-type="collection" publication-format="electronic">
        <month>02</month>
        <year>2009</year>
      </pub-date>
      <volume>92</volume>
      <issue>2</issue>
      <fpage>127</fpage>
      <lpage>134</lpage>
      <history>
        <date date-type="received">
          <day>21</day>
          <month>01</month>
          <year>2008</year>
        </date>
        <date date-type="rev-recd">
          <day>18</day>
          <month>02</month>
          <year>2008</year>
        </date>
        <date date-type="accepted">
          <day>29</day>
          <month>02</month>
          <year>2008</year>
        </date>
      </history>
      <permissions>
        <license license-type="open-access" xlink:href="http://creativecommons.org/licenses/by-nc/4.0/" xml:lang="en">
          <license-p>This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.</license-p>
        </license>
      </permissions>
      <abstract>
        <p>FUNDAMENTO: Insufici&#234;ncia card&#237;aca cr&#244;nica &#233; um grave dist&#250;rbio cardiovascular. OBJETIVO: O objetivo deste estudo foi avaliar prospectivamente se o resultado do teste de caminhada de 6 minutos (TC-6M) se correlaciona com as vari&#225;veis ecocardiogr&#225;ficas em pacientes portadores de disfun&#231;&#227;o sist&#243;lica do ventr&#237;culo esquerdo e insufici&#234;ncia card&#237;aca cr&#244;nica est&#225;vel. M&#201;TODOS: Foram estudados prospectivamente 52 pacientes (65% homens; m&#233;dia de idade de 60&#177;11 anos) portadores de insufici&#234;ncia card&#237;aca cr&#244;nica secund&#225;ria &#224; cardiopatia isqu&#234;mica ou miocardiopatia idiop&#225;tica. Todos os pacientes apresentavam disfun&#231;&#227;o sist&#243;lica do ventr&#237;culo esquerdo (fra&#231;&#227;o de eje&#231;&#227;o &lt;0.45) e encontravam-se em insufici&#234;ncia card&#237;aca classe funcional II ou III da NYHA. Foram realizados um estudo de eco-Doppler e um TC-6M no mesmo dia. RESULTADOS: O TC-6M apresentou correla&#231;&#227;o moderada, mas estatisticamente significante, com o di&#226;metro sist&#243;lico final - DSF (r=-0,46; p=0,0006), com a fra&#231;&#227;o de encurtamento - FEn (r=0,52; p=0,0001) e com a fra&#231;&#227;o de eje&#231;&#227;o (FE) (r=0,5; p=0,0001), e apresentou correla&#231;&#227;o fraca, mas estatisticamente significante, com o &#237;ndice de desempenho mioc&#225;rdico - IDM (r=-0,39; p=0,0046), a rela&#231;&#227;o E/A (tric&#250;spide) (r=-0,333; p=0,016), o tempo de acelera&#231;&#227;o do fluxo pulmonar (r=0,328; p=0,018), e com a amplitude do eixo longo lateral (r=0,283; p=0,04). O modelo de regress&#227;o linear demonstrou que a idade (&#967;2=-0,59, p=&lt;0,001), o padr&#227;o de enchimento restritivo transmitral (&#967;2=-0,44, p=0,004) e a dimens&#227;o sist&#243;lica final do ventr&#237;culo esquerdo (&#967;2=-0,34, p=0,012) foram fatores independentes que influenciam o TC-6M. CONCLUS&#195;O: Em pacientes portadores de insufici&#234;ncia card&#237;aca decorrente de disfun&#231;&#227;o sist&#243;lica do ventr&#237;culo esquerdo, o TC-6M como ferramenta de avalia&#231;&#227;o cl&#237;nica da capacidade funcional apresenta uma correla&#231;&#227;o significante com os principais par&#226;metros da fun&#231;&#227;o sist&#243;lica global do VE e com o IDM do VE. Em pacientes com disfun&#231;&#227;o sist&#243;lica do VE, a idade, o padr&#227;o de enchimento restritivo transmitral e a dimens&#227;o sist&#243;lica do ventr&#237;culo esquerdo mostraram-se independentemente associados ao TC-6M.</p>
      </abstract>
      <kwd-group xml:lang="pt" kwd-group-type="author-generated">
        <kwd>Insufici&#234;ncia card&#237;aca</kwd>
        <kwd>ecocardiografia</kwd>
        <kwd>caminhada</kwd>
        <kwd>qualidade de vida</kwd>
      </kwd-group>
      <pub-date publication-format="electronic" date-type="pub">
        <day>06</day>
        <month>04</month>
        <year>2009</year>
      </pub-date>
    </article-meta>
  </front>
  <body>
    <p>ARTIGO ORIGINAL </p>
    <p> INSUFICI&#202;NCIA CARD&#205;ACA</p>
    <p>Ecocardiografia e teste de caminhada de 6 minutos na disfun&#231;&#227;o sist&#243;lica do ventr&#237;culo esquerdo</p>
    <p>
      <bold>Venera Berisha<sup>I</sup>; Gani Bajraktari<sup>I</sup>; Dritero Dobra<sup>II</sup>; Edmond Haliti<sup>I</sup>; Reshat Bajrami<sup>I</sup>; Shpend Elezi<sup>II</sup></bold>
    </p>
    <p><sup>I</sup>Segunda Divis&#227;o de Cardiologia - Cl&#237;nica Geral - Universidade Centro Cl&#237;nico de Kosova, Prishtina - Kosovo </p>
    <p><sup>II</sup>Faculdade de Medicina, Universidade de Prishtina, Prishtina - Kosovo</p>
    <p>
      <xref ref-type="corresp" rid="end">Correspond&#234;ncia</xref>
    </p>
    <p>
      <bold>RESUMO</bold>
    </p>
    <p><bold>FUNDAMENTO:</bold> Insufici&#234;ncia card&#237;aca cr&#244;nica &#233; um grave dist&#250;rbio cardiovascular. </p>
    <p><bold>OBJETIVO:</bold> O objetivo deste estudo foi avaliar prospectivamente se o resultado do teste de caminhada de 6 minutos (TC-6M) se correlaciona com as vari&#225;veis ecocardiogr&#225;ficas em pacientes portadores de disfun&#231;&#227;o sist&#243;lica do ventr&#237;culo esquerdo e insufici&#234;ncia card&#237;aca cr&#244;nica est&#225;vel. </p>
    <p><bold>M&#201;TODOS:</bold> Foram estudados prospectivamente 52 pacientes (65% homens; m&#233;dia de idade de 60&#177;11 anos) portadores de insufici&#234;ncia card&#237;aca cr&#244;nica secund&#225;ria &#224; cardiopatia isqu&#234;mica ou miocardiopatia idiop&#225;tica. Todos os pacientes apresentavam disfun&#231;&#227;o sist&#243;lica do ventr&#237;culo esquerdo (fra&#231;&#227;o de eje&#231;&#227;o <underline>&lt;</underline>0.45) e encontravam-se em insufici&#234;ncia card&#237;aca classe funcional II ou III da NYHA. Foram realizados um estudo de eco-Doppler e um TC-6M no mesmo dia. </p>
    <p><bold>RESULTADOS:</bold> O TC-6M apresentou correla&#231;&#227;o moderada, mas estatisticamente significante, com o di&#226;metro sist&#243;lico final - DSF (r=-0,46; p=0,0006), com a fra&#231;&#227;o de encurtamento - FEn (r=0,52; p=0,0001) e com a fra&#231;&#227;o de eje&#231;&#227;o (FE) (r=0,5; p=0,0001), e apresentou correla&#231;&#227;o fraca, mas estatisticamente significante, com o &#237;ndice de desempenho mioc&#225;rdico - IDM (r=-0,39; p=0,0046), a rela&#231;&#227;o E/A (tric&#250;spide) (r=-0,333; p=0,016), o tempo de acelera&#231;&#227;o do fluxo pulmonar (r=0,328; p=0,018), e com a amplitude do eixo longo lateral (r=0,283; p=0,04). O modelo de regress&#227;o linear demonstrou que a idade (&#967;<sup>2</sup>=-0,59, p=&lt;0,001), o padr&#227;o de enchimento restritivo transmitral (&#967;<sup>2</sup>=-0,44, p=0,004) e a dimens&#227;o sist&#243;lica final do ventr&#237;culo esquerdo (&#967;<sup>2</sup>=-0,34, p=0,012) foram fatores independentes que influenciam o TC-6M. </p>
    <p><bold>CONCLUS&#195;O:</bold> Em pacientes portadores de insufici&#234;ncia card&#237;aca decorrente de disfun&#231;&#227;o sist&#243;lica do ventr&#237;culo esquerdo, o TC-6M como ferramenta de avalia&#231;&#227;o cl&#237;nica da capacidade funcional apresenta uma correla&#231;&#227;o significante com os principais par&#226;metros da fun&#231;&#227;o sist&#243;lica global do VE e com o IDM do VE. Em pacientes com disfun&#231;&#227;o sist&#243;lica do VE, a idade, o padr&#227;o de enchimento restritivo transmitral e a dimens&#227;o sist&#243;lica do ventr&#237;culo esquerdo mostraram-se independentemente associados ao TC-6M.</p>
    <p><bold>Palavras-chave:</bold> Insufici&#234;ncia card&#237;aca, ecocardiografia, caminhada, qualidade de vida.</p>
    <p>
      <bold>Introdu&#231;&#227;o</bold>
    </p>
    <p>A insufici&#234;ncia card&#237;aca cr&#244;nica &#233; uma das principais doen&#231;as cardiovasculares, e sua incid&#234;ncia e preval&#234;ncia s&#227;o crescentes<sup>1</sup>. A ecocardiografia bidimensional com Doppler &#233; um m&#233;todo sens&#237;vel e n&#227;o invasivo de detec&#231;&#227;o de anormalidades card&#237;acas e disfun&#231;&#227;o sist&#243;lica e/ou diast&#243;lica<sup>2</sup>. As vari&#225;veis de enchimento diast&#243;lico permitem a identifica&#231;&#227;o posterior de subgrupos com progn&#243;sticos de longo prazo divergentes<sup>3</sup>. Recentemente, foi sugerido o &#237;ndice de desempenho mioc&#225;rdico (IDM) para avaliar a fun&#231;&#227;o ventricular<sup>4</sup>. O IDM &#233; calculado a partir dos registros do Doppler pulsado das velocidades de entrada e sa&#237;da dos ventr&#237;culos e, portanto, combina o desempenho ventricular sist&#243;lico e diast&#243;lico. Ele reflete a fun&#231;&#227;o ventricular global e &#233; menos afetado por anormalidades segmentares localizadas da mobilidade da parede, al&#233;m de desempenhar um papel progn&#243;stico importante no diagn&#243;stico de insufici&#234;ncia card&#237;aca<sup>5</sup> e na previs&#227;o de eventos card&#237;acos em pacientes com infarto agudo do mioc&#225;rdio<sup>6</sup>. A gravidade da insufici&#234;ncia card&#237;aca congestiva &#233; geralmente graduada de acordo com os sintomas dos pacientes, particularmente com as atividades f&#237;sicas que induzem dispn&#233;ia ou fadiga. A classifica&#231;&#227;o funcional de insufici&#234;ncia card&#237;aca da NYHA satisfaz apenas alguns desses crit&#233;rios. Entretanto, essa classifica&#231;&#227;o &#233; baseada na auto-avalia&#231;&#227;o do paciente e sua confiabilidade ainda &#233; discut&#237;vel<sup>7</sup>. O instrumento ideal para a estratifica&#231;&#227;o de risco e estabelecimento da melhor conduta cl&#237;nica para os pacientes portadores de insufici&#234;ncia card&#237;aca congestiva deve ser objetivo, simples, barato e seguro. A capta&#231;&#227;o m&#225;xima de oxig&#234;nio, medida durante o teste de esfor&#231;o cardiopulmonar, &#233; um par&#226;metro mais objetivo para avaliar a capacidade funcional e predizer a sobreviv&#234;ncia em pacientes com insufici&#234;ncia card&#237;aca<sup>8-10</sup>. No entanto, esse m&#233;todo est&#225; restrito apenas aos centros especializados, porque requer equipamento sofisticado e pessoal especialmente treinado.</p>
    <p>O teste de caminhada de 6 minutos (TC-6M) foi proposto como uma t&#233;cnica alternativa simples e precisa para a medi&#231;&#227;o da capacidade de esfor&#231;o sub-m&#225;xima em pacientes portadores de insufici&#234;ncia card&#237;aca congestiva<sup>11</sup>. Considera-se que esteja realisticamente relacionado &#224; atividade f&#237;sica di&#225;ria. Conseq&#252;entemente, foi incorporado a estudos de avalia&#231;&#227;o da capacidade de esfor&#231;o<sup>12,13</sup>, de qualidade de vida<sup>14</sup>, de efic&#225;cia de novos agentes terap&#234;uticos<sup>15-17</sup> incluindo beta-bloqueadores<sup>18-22</sup>, de programas de treinamento f&#237;sico<sup>23</sup> e de estratifica&#231;&#227;o progn&#243;stica<sup>24-29</sup>.</p>
    <p>O objetivo do presente estudo foi avaliar a rela&#231;&#227;o entre os par&#226;metros do ecocardiograma bidimensional com Doppler e o TC-6M em pacientes com insufici&#234;ncia card&#237;aca e disfun&#231;&#227;o sist&#243;lica do ventr&#237;culo esquerdo. O TC-6M &#233; usado como medida indireta da qualidade de vida; portanto, par&#226;metros ecocardiogr&#225;ficos que apresentam associa&#231;&#227;o independente com o TC-6M facilitariam a previs&#227;o da qualidade de vida.</p>
    <p>
      <bold>M&#233;todos</bold>
    </p>
    <p>
      <bold>Popula&#231;&#227;o do estudo</bold>
    </p>
    <p>O grupo do estudo incluiu 52 pacientes portadores de insufici&#234;ncia card&#237;aca cr&#244;nica est&#225;vel secund&#225;ria &#224; cardiopatia isqu&#234;mica ou miocardiopatia idiop&#225;tica encaminhados &#224; Segunda Divis&#227;o de Cardiologia da Cl&#237;nica Geral da Universidade Centro Cl&#237;nico de Kosova em Prishtina, Kosovo, entre dezembro de 2005 e abril de 2007.</p>
    <p>A m&#233;dia de idade foi de 60&#177;11 anos. A etiologia da insufici&#234;ncia card&#237;aca foi miocardiopatia dilatada idiop&#225;tica em 19 pacientes e miocardiopatia isqu&#234;mica em 33. Todos os pacientes apresentavam aumento do ventr&#237;culo esquerdo (dimens&#227;o diast&#243;lica do ventr&#237;culo esquerdo [VE] &gt;5,7cm) e disfun&#231;&#227;o sist&#243;lica global do ventr&#237;culo esquerdo (fra&#231;&#227;o de eje&#231;&#227;o do ventr&#237;culo esquerdo [FEVE] &lt;0,45), e todos se encontravam em insufici&#234;ncia card&#237;aca est&#225;vel classe funcional II ou III da <italic>New York Heart Association</italic> (NYHA). A capacidade funcional foi classe II em 27 pacientes e classe III nos 25 restantes. As caracter&#237;sticas cl&#237;nicas e laboratoriais dos pacientes est&#227;o resumidas na <xref ref-type="table" rid="tab01">Tabela 1</xref>.</p>
    <table-wrap id="tab01">
      <graphic xlink:href="1678-4170-abc-92-02-0127-00009-gt01.jpg"/></table-wrap>
    <p>Foram exclu&#237;dos do estudo os pacientes com dist&#250;rbio de ritmo (fibrila&#231;&#227;o atrial, arritmias ventriculares graves), os que apresentavam insufici&#234;ncia card&#237;aca descompensada, limita&#231;&#227;o da atividade f&#237;sica devido a fatores outros que n&#227;o a dispn&#233;ia de esfor&#231;o e fadiga (por exemplo, artrite), e os portadores de insufici&#234;ncia renal de moderada a grave, com doen&#231;a pulmonar obstrutiva cr&#244;nica. Tamb&#233;m foram exclu&#237;dos os pacientes que haviam apresentado angina inst&#225;vel, infarto agudo do mioc&#225;rdio ou acidente vascular cerebral, anemia e quaisquer doen&#231;as febris ou infecciosas.</p>
    <p>O estudo foi aprovado pelo Comit&#234; de &#201;tica da institui&#231;&#227;o e todos os pacientes assinaram o termo de consentimento livre e esclarecido. O tratamento cl&#237;nico padr&#227;o com, por exemplo, inibidores da ECA, beta-bloqueadores, digoxina e diur&#233;ticos foi otimizado individualmente com base nos sintomas e na fun&#231;&#227;o renal pelo menos duas semanas antes do teste ergom&#233;trico. Todos os pacientes continuaram recebendo a medica&#231;&#227;o de rotina quando foram realizados o ecocardiograma e o TC-6M.</p>
    <p>
      <bold>Coleta de dados</bold>
    </p>
    <p>Para todos os indiv&#237;duos foi obtido o hist&#243;rico cl&#237;nico e realizados exame f&#237;sico e exames bioqu&#237;micos de rotina: contagem de hem&#225;cias, leuc&#243;citos, hemoglobina, hemat&#243;crito, VHS, ur&#233;ia, creatinina, glicemia, colesterol, triglic&#233;rides, e marcadores inflamat&#243;rios (fibrinog&#234;nio, PCR). Foram tamb&#233;m medidos o peso, estatura, cintura e quadril.</p>
    <p>
      <bold>Exames ecocardiogr&#225;ficos</bold>
    </p>
    <p>O exame ecocardiogr&#225;fico foi feito atrav&#233;s do ecocardi&#243;grafo Philips Intelligent E-33 com transdutor multifreq&#252;&#234;ncia e imagem harm&#244;nica, conforme conviesse. Todos os ecocardiogramas foram realizados pelo mesmo investigador. O estudo ecocardiogr&#225;fico foi realizado em dec&#250;bito lateral esquerdo, nas proje&#231;&#245;es do eixo longo paraesternal e de quatro c&#226;maras.</p>
    <p>Os registros transversais unidimensionais guiados bidimensionalmente do eixo curto do VE foram realizados atrav&#233;s da proje&#231;&#227;o do eixo longo paraesternal esquerdo, com o cursor nas pontas dos folhetos da v&#225;lvula mitral. A fra&#231;&#227;o de encurtamento foi calculada como a queda percentual na dimens&#227;o da cavidade do VE durante a s&#237;stole em compara&#231;&#227;o com a do final da di&#225;stole. A fra&#231;&#227;o de eje&#231;&#227;o do ventr&#237;culo esquerdo foi estimada atrav&#233;s do m&#233;todo biplano de Simpson. A dimens&#227;o do &#225;trio esquerdo foi medida a partir dos registros de ultrassom unidimensional com o cursor cruzando a raiz a&#243;rtica ao n&#237;vel dos folhetos da v&#225;lvula a&#243;rtica. Os registros em modo unidimensional do eixo longo do VE foram obtidos com o cursor posicionado nos &#226;ngulos lateral e septal do anel mitral, e os do eixo longo do ventr&#237;culo direito com o cursor posicionado no &#226;ngulo lateral do anel tric&#250;spide. Todos os registros em modo unidimensional foram obtidos com aproxima&#231;&#227;o para que as imagens fossem melhores e, assim, as medidas fossem mais exatas.</p>
    <p>A fun&#231;&#227;o diast&#243;lica dos ventr&#237;culos direito e esquerdo foi avaliada por Doppler pulsado. O volume de amostra do Doppler pulsado foi posicionado nas pontas dos folhetos mitral e tric&#250;spide, respectivamente. Foram registradas as ondas E e a onda A, a partir das quais foi calculada a rela&#231;&#227;o E/A, e o tempo de desacelera&#231;&#227;o da onda E (TD-E). Tamb&#233;m foram registradas a onda Er, onda Ar e a rela&#231;&#227;o Er/Ar.</p>
    <p>O IDM foi medido a partir dos intervalos de tempo da velocidade do fluxo de entrada mitral e fluxo de sa&#237;da do VE, conforme descrito por Tei e cols<sup>30</sup>. O intervalo <italic>a </italic>medido a partir do t&#233;rmino at&#233; o in&#237;cio do fluxo de entrada mitral &#233; igual &#224; soma do tempo de contra&#231;&#227;o isovolum&#233;trica (TCI), tempo de eje&#231;&#227;o (TE) e tempo de relaxamento isovolum&#233;trico (TRI). O tempo de eje&#231;&#227;o do ventr&#237;culo esquerdo <italic>b </italic>&#233; a dura&#231;&#227;o do perfil de velocidade do fluxo de sa&#237;da do ventr&#237;culo esquerdo. Assim, a soma do TCI e do TRI foi obtida subtraindo-se <italic>b </italic>de <italic>a</italic>. O &#237;ndice combinado da fun&#231;&#227;o sist&#243;lica e diast&#243;lica (soma de TCI e TRI dividida pelo tempo de eje&#231;&#227;o) foi calculado como (<italic>a</italic> - <italic>b</italic>) / <italic>b </italic>(<xref ref-type="fig" rid="fig01">Figura 1</xref>). O TRI pode ser medido subtraindo-se o intervalo <italic>d</italic>, entre a onda R e o t&#233;rmino do fluxo de sa&#237;da do VE, do intervalo <italic>c</italic>, entre a onda R e o in&#237;cio do fluxo de entrada mitral. O TCI foi calculado subtraindo-se o TRI de <italic>a-b.</italic></p>
    <fig id="fig01">
      <graphic xlink:href="1678-4170-abc-92-02-0127-00009-gf01.jpg"/></fig>
    <p>A gravidade da insufici&#234;ncia mitral foi avaliada por Doppler colorido e Doppler cont&#237;nuo e classificada como leve, moderada ou grave, de acordo com a dist&#226;ncia do jato a partir do orif&#237;cio da v&#225;lvula e do perfil de velocidade do fluxo, respectivamente, conforme recomendado pela Sociedade Americana de Ecocardiografia<sup>31</sup>. Da mesma forma, avaliou-se a insufici&#234;ncia tric&#250;spide atrav&#233;s de Doppler colorido e Doppler cont&#237;nuo a partir da proje&#231;&#227;o apical de quatro c&#226;maras. Uma queda na press&#227;o transvalvar tric&#250;spide retr&#243;grada &gt; 35 mmHg foi considerada como sinal de hipertens&#227;o pulmonar quando n&#227;o havia dilata&#231;&#227;o do &#225;trio direito.</p>
    <p>
      <bold>Teste de caminhada de 6 minutos</bold>
    </p>
    <p>Dentro de 24 horas da realiza&#231;&#227;o do ecocardiograma, foi realizado um TC-6M em um corredor plano. O teste foi aplicado por uma enfermeira que desconhecia os resultados do ecocardiograma. De acordo com o m&#233;todo de Gyatt e cols<sup>11,12</sup>, todos os pacientes foram informados do objetivo, m&#233;todos e uso dos resultados do teste de caminhada de 6 minutos. O TC-6M foi realizado de acordo com um protocolo padronizado, entre as 10 e 16 horas, ap&#243;s medica&#231;&#227;o habitual<sup>11</sup>. Foi usado um corredor plano de 15 m, livre de obst&#225;culos, com cadeiras posicionadas em cada uma de suas extremidades. Os pacientes foram orientados a andar a maior dist&#226;ncia poss&#237;vel, virando 180&#186; a cada 15m, dentro do limite de tempo de seis minutos. Os pacientes andaram sozinhos para que n&#227;o houvesse influ&#234;ncia sobre a velocidade da caminhada e foram solicitados a andar a maior dist&#226;ncia poss&#237;vel durante seis minutos. Os pacientes podiam descansar, se precisassem, e o tempo restante lhes era informado a cada dois minutos. Ao final dos seis minutos, o m&#233;dico media a dist&#226;ncia total percorrida pelo paciente.</p>
    <p>
      <bold>An&#225;lise estat&#237;stica</bold>
    </p>
    <p>Os dados foram apresentados como m&#233;dia &#177; DP ou propor&#231;&#245;es (% de pacientes). Os dados cont&#237;nuos foram comparados usando-se o teste <italic>t</italic> de <italic>Student</italic> bicaudal n&#227;o pareado. Os dados discretos foram comparados atrav&#233;s do teste do qui quadrado. A correla&#231;&#227;o entre vari&#225;veis foi feita atrav&#233;s do teste de correla&#231;&#227;o de Pearson. Valores de p &lt; 0.05 foram considerados estatisticamente significantes. Foi realizada an&#225;lise multivariada atrav&#233;s do modelo de regress&#227;o linear. Os fatores inclu&#237;dos nesse modelo foram: idade, padr&#227;o de enchimento restritivo transmitral, dimens&#227;o sist&#243;lica do ventr&#237;culo esquerdo, &#237;ndice de desempenho mioc&#225;rdico e diabetes mellitus.</p>
    <p>
      <bold>Resultados</bold>
    </p>
    <p>As caracter&#237;sticas cl&#237;nicas e laboratoriais dos 52 pacientes inclu&#237;dos no estudo s&#227;o mostradas na <xref ref-type="table" rid="tab01">Tabela 1</xref>, e as medidas ecocardiogr&#225;ficas e de Doppler, na <xref ref-type="table" rid="tab02">Tabela 2</xref>. Houve uma correla&#231;&#227;o moderada, mas estatisticamente significante entre o TC-6M e a espessura da parede posterior do VE (r= 0,49; p&lt;0,001), dimens&#227;o sist&#243;lica final do ventr&#237;culo esquerdo (r=0,46, p&lt;0,001, <xref ref-type="fig" rid="fig02">Fig. 2</xref>), fra&#231;&#227;o de encurtamento do VE (r = 0,517, p&lt;0,001, <xref ref-type="fig" rid="fig03">Fig. 3</xref>) e FEVE (r = 0,50, p&lt;0,001), ao passo que houve uma correla&#231;&#227;o fraca, mas estatisticamente significante com o &#237;ndice de desempenho mioc&#225;rdico - IDM (r=-0,39; p=0,0046, <xref ref-type="fig" rid="fig04">Fig. 4</xref>), rela&#231;&#227;o E/A (tric&#250;spide) (r=-0,333; p=0,016), tempo de acelera&#231;&#227;o do fluxo pulmonar (r=0,328; p=0,018) e amplitude do eixo longo lateral (r=0,283; p=0,04) (<xref ref-type="table" rid="tab03">Tabela 3</xref>). As dimens&#245;es da aorta, &#225;trio direito, espessura do septo interventricular, onda E, onda A, rela&#231;&#227;o E/A, tempo de desacelera&#231;&#227;o da onda E, onda E (tric&#250;spide), onda A (tric&#250;spide), rela&#231;&#227;o E (tric&#250;spide)/A (tric&#250;spide), tempo de desacelera&#231;&#227;o de E (tric&#250;spide) e amplitude do eixo longo do septo do VE n&#227;o apresentaram correla&#231;&#227;o significante com o TC-6M (<xref ref-type="table" rid="tab03">Tabela 3</xref>).</p>
    <table-wrap id="tab02">
      <graphic xlink:href="1678-4170-abc-92-02-0127-00009-gt02.jpg"/></table-wrap>
    <fig id="fig02">
      <graphic xlink:href="1678-4170-abc-92-02-0127-00009-gf02.jpg"/></fig>
    <fig id="fig03">
      <graphic xlink:href="1678-4170-abc-92-02-0127-00009-gf03.jpg"/></fig>
    <fig id="fig04">
      <graphic xlink:href="1678-4170-abc-92-02-0127-00009-gf04.jpg"/></fig>
    <table-wrap id="tab03">
      <graphic xlink:href="1678-4170-abc-92-02-0127-00009-gt03.jpg"/></table-wrap>
    <p>Foi realizada an&#225;lise multivariada atrav&#233;s do modelo de regress&#227;o linear. Os resultados desse modelo (<xref ref-type="table" rid="tab04">Tabela 4</xref>) demonstraram que a idade, o padr&#227;o de enchimento restritivo transmitral e a dimens&#227;o sist&#243;lica final do ventr&#237;culo esquerdo foram fatores independentes que influenciaram o TC-6M. Todos esses par&#226;metros mostraram-se inversamente relacionados com o TC-6M. A idade dos pacientes surgiu como o mais forte fator preditivo independente, seguido pelo padr&#227;o de enchimento restritivo e dimens&#227;o sist&#243;lica final do ventr&#237;culo esquerdo.</p>
    <table-wrap id="tab04">
      <graphic xlink:href="1678-4170-abc-92-02-0127-00009-gt04.jpg"/></table-wrap>
    <p>
      <bold>Discuss&#227;o</bold>
    </p>
    <p>At&#233; onde sabemos, este &#233; o primeiro estudo a correlacionar o desempenho do TC-6M em pacientes portadores de insufici&#234;ncia card&#237;aca cr&#244;nica. O principal achado do nosso estudo foi que o TC-6M apresenta uma moderada, mas estatisticamente significante correla&#231;&#227;o com a dimens&#227;o sist&#243;lica do VE, com par&#226;metros da fun&#231;&#227;o sist&#243;lica global do VE e IDM do VE, bem como com a fun&#231;&#227;o sist&#243;lica dos ventr&#237;culos direito e esquerdo no eixo longo em pacientes portadores de insufici&#234;ncia card&#237;aca cr&#244;nica est&#225;vel decorrente de disfun&#231;&#227;o sist&#243;lica do VE.</p>
    <p>Outro achado do nosso estudo foi que a idade, o padr&#227;o de enchimento restritivo transmitral e a dimens&#227;o sist&#243;lica do ventr&#237;culo esquerdo encontram-se independentemente relacionados com o TC-6M em pacientes portadores de insufici&#234;ncia card&#237;aca cr&#244;nica est&#225;vel decorrente de disfun&#231;&#227;o sist&#243;lica do ventr&#237;culo esquerdo sem doen&#231;a valvar reum&#225;tica associada.</p>
    <p>A insufici&#234;ncia card&#237;aca &#233; uma entidade epidemiol&#243;gica que est&#225; crescendo no mundo todo, e hoje representa um problema de sa&#250;de importante na maioria dos pa&#237;ses desenvolvidos<sup>1</sup>. A medida da qualidade de vida em portadores de insufici&#234;ncia card&#237;aca tem-se mostrado mais enganosa do que se imaginava. Ainda n&#227;o est&#225; claro o que &#233; melhor para a avalia&#231;&#227;o da gradua&#231;&#227;o da insufici&#234;ncia card&#237;aca: se o julgamento do m&#233;dico, o uso da classifica&#231;&#227;o funcional da NYHA, ou se o uso de diferentes question&#225;rios sofisticados.</p>
    <p>O TC-6M foi originalmente utilizado por m&#233;dicos para avaliar pneumopatas<sup>32,33</sup>, e posteriormente foi introduzido como uma medida objetiva alternativa da capacidade de esfor&#231;o sub-m&#225;xima de pacientes portadores de insufici&#234;ncia card&#237;aca congestiva<sup>11</sup>. Estudos anteriores mostram resultados controversos sobre a correla&#231;&#227;o do TC-6M com a capacidade de esfor&#231;o funcional em portadores de insufici&#234;ncia card&#237;aca cr&#244;nica. Demonstrou-se que o TC-6M se correlacionou com a capta&#231;&#227;o m&#225;xima de oxig&#234;nio na miocardiopatia dilatada e tem um valor preditivo nesses pacientes<sup>34-36</sup>. O TC-6M tamb&#233;m se mostrou um marcador progn&#243;stico &#250;til nesses pacientes<sup>26,27,37</sup>. No entanto, Opasich e cols<sup>38</sup> demonstraram que o teste de caminhada de seis minutos n&#227;o est&#225; relacionado com a fun&#231;&#227;o card&#237;aca, est&#225; apenas moderadamente relacionado com a capacidade de esfor&#231;o em portadores de insufici&#234;ncia card&#237;aca cr&#244;nica de moderada a grave.</p>
    <p>Tamb&#233;m foi provado que a dist&#226;ncia percorrida no TC-6M melhorou ap&#243;s o seguimento de pacientes com disfun&#231;&#227;o sist&#243;lica do VE que receberam inibidores da ECA<sup>39,40</sup>, beta-bloqueadores de nova gera&#231;&#227;o<sup>18-22</sup> e que foram submetidos a treinamento f&#237;sico<sup>23</sup>.</p>
    <p>H&#225; v&#225;rias implica&#231;&#245;es cl&#237;nicas que poderiam ser sugeridas a partir deste estudo. V&#225;rios par&#226;metros ecocardiogr&#225;ficos importantes mostram-se independentemente relacionados com o TC-6M e, portanto, podem ser usados para prever a qualidade de vida dos pacientes. A idade apareceu como um fator independente inversamente relacionado com o TC-6M. Portanto, independentemente dos resultados da ecocardiografia, a qualidade de vida se deteriora com a idade provavelmente devido a fatores complexos associados ao envelhecimento.</p>
    <p>O pequeno n&#250;mero de pacientes poderia ser apontado como limita&#231;&#227;o deste estudo, especialmente pela an&#225;lise multivariada abrangente.</p>
    <p>Concluindo, em pacientes portadores de insufici&#234;ncia card&#237;aca decorrente de disfun&#231;&#227;o sist&#243;lica do ventr&#237;culo esquerdo, o TC-6M. como ferramenta de avalia&#231;&#227;o cl&#237;nica da capacidade funcional, apresenta uma correla&#231;&#227;o importante com os principais par&#226;metros da fun&#231;&#227;o sist&#243;lica global do VE, bem como com o IDM do VE. Em pacientes com disfun&#231;&#227;o sist&#243;lica do VE, a idade, o padr&#227;o de enchimento restritivo transmitral e a dimens&#227;o sist&#243;lica do ventr&#237;culo esquerdo mostraram-se independentemente associados ao TC-6M.</p>
    <p>
      <bold>Potencial Conflito de Interesses</bold>
    </p>
    <p>Declaro n&#227;o haver conflito de interesses pertinentes.</p>
    <p>
      <bold>Fontes de Financiamento</bold>
    </p>
    <p>O presente estudo n&#227;o teve fontes de financiamento externas.</p>
    <p>
      <bold>Vincula&#231;&#227;o Acad&#234;mica</bold>
    </p>
    <p>N&#227;o h&#225; vincula&#231;&#227;o deste estudo a programas de p&#243;s-gradua&#231;&#227;o.</p>
    <p>
      <fn id="end" fn-type="corresp">
        <p>Correspond&#234;ncia:</p>
        <p> Gani Bajraktari </p>
        <p> Bregu i Diellit, Z.Q. 7/19 </p>
        <p> 10000, Prishtina - Kosovo </p>
        <p> E-mail: </p>
        <p>
          <email xlink:href="ganibaj@hotmail.com">ganibaj@hotmail.com</email>
        </p>
      </fn>
    </p>
    <p> Artigo recebido em 21/01/08; revisado recebido em 18/02/08; aceito em 29/02/08.</p>
  </body>
  <back>
    <ref-list>
      <ref id="B1">
        <mixed-citation>1. Hoes AW, Mosterd A, Grobbee DE. An epidemic    of heart failure? Recent evidence from Europe. Eur Heart J. 1998; 19 (Suppl    1): I 2-I 9.</mixed-citation>
        <element-citation publication-type="journal">
          <article-title>An epidemic of heart failure?: Recent evidence from Europe</article-title>
          <source>Eur Heart J.</source>
          <date>
            <year>1998</year>
          </date>
          <fpage>I 2</fpage>
          <lpage>I 9</lpage>
          <volume>19</volume>
          <person-group person-group-type="author">
            <name>
              <surname>Hoes</surname>
              <given-names>AW</given-names>
            </name>
            <name>
              <surname>Mosterd</surname>
              <given-names>A</given-names>
            </name>
            <name>
              <surname>Grobbee</surname>
              <given-names>DE</given-names>
            </name>
          </person-group>
        </element-citation>
      </ref>
      <ref id="B2">
        <mixed-citation>2. DeMaria AN, Wiswnbaugh TW, Smith MD, Harrison    MR, Berk MR. Doppler echocardiographic evaluation of diastolic dysfunction.    Circulation. 1991; 84: 288-95.</mixed-citation>
        <element-citation publication-type="journal">
          <article-title>Doppler echocardiographic evaluation of diastolic dysfunction</article-title>
          <source>Circulation</source>
          <date>
            <year>1991</year>
          </date>
          <fpage>288</fpage>
          <lpage>95</lpage>
          <volume>84</volume>
          <person-group person-group-type="author">
            <name>
              <surname>DeMaria</surname>
              <given-names>AN</given-names>
            </name>
            <name>
              <surname>Wiswnbaugh</surname>
              <given-names>TW</given-names>
            </name>
            <name>
              <surname>Smith</surname>
              <given-names>MD</given-names>
            </name>
            <name>
              <surname>Harrison</surname>
              <given-names>MR</given-names>
            </name>
            <name>
              <surname>Berk</surname>
              <given-names>MR</given-names>
            </name>
          </person-group>
        </element-citation>
      </ref>
      <ref id="B3">
        <mixed-citation>3. Rihal CS, Nishimura RA, Hatle LK, Bailey KR,    Tajik AJ. Systolic and diastolic dysfunction in patients with clinical diagnosis    of dilated cardiomyopathy: relation to symptoms and prognosis. Circulation.    1994; 90: 2772-9.</mixed-citation>
        <element-citation publication-type="journal">
          <article-title>Systolic and diastolic dysfunction in patients with clinical diagnosis of dilated cardiomyopathy: relation to symptoms and prognosis</article-title>
          <source>Circulation</source>
          <date>
            <year>1994</year>
          </date>
          <fpage>2772</fpage>
          <lpage>9</lpage>
          <volume>90</volume>
          <person-group person-group-type="author">
            <name>
              <surname>Rihal</surname>
              <given-names>CS</given-names>
            </name>
            <name>
              <surname>Nishimura</surname>
              <given-names>RA</given-names>
            </name>
            <name>
              <surname>Hatle</surname>
              <given-names>LK</given-names>
            </name>
            <name>
              <surname>Bailey</surname>
              <given-names>KR</given-names>
            </name>
            <name>
              <surname>Tajik</surname>
              <given-names>AJ</given-names>
            </name>
          </person-group>
        </element-citation>
      </ref>
      <ref id="B4">
        <mixed-citation>4. Tei C, Ling LH, Hodge DO, Bailey KR, Oh JK,    Rodeheffer RJ, et al. New index of combined systolic and diastolic myocardial    performance: a simple and reproducible measure of cardiac function- a study    in normal and dilated cardiomyopathy. J Cardiol. 1995; 26 (6): 357-66.</mixed-citation>
        <element-citation publication-type="journal">
          <article-title>New index of combined systolic and diastolic myocardial performance: a simple and reproducible measure of cardiac function- a study in normal and dilated cardiomyopathy</article-title>
          <source>J Cardiol</source>
          <date>
            <year>1995</year>
          </date>
          <fpage>357</fpage>
          <lpage>66</lpage>
          <issue>6</issue>
          <volume>26</volume>
          <person-group person-group-type="author">
            <name>
              <surname>Tei</surname>
              <given-names>C</given-names>
            </name>
            <name>
              <surname>Ling</surname>
              <given-names>LH</given-names>
            </name>
            <name>
              <surname>Hodge</surname>
              <given-names>DO</given-names>
            </name>
            <name>
              <surname>Bailey</surname>
              <given-names>KR</given-names>
            </name>
            <name>
              <surname>Oh</surname>
              <given-names>JK</given-names>
            </name>
            <name>
              <surname>Rodeheffer</surname>
              <given-names>RJ</given-names>
            </name>
          </person-group>
        </element-citation>
      </ref>
      <ref id="B5">
        <mixed-citation>5. St John Sutton M, Wiegers SE. The Tei index-    a role in the diagnosis of heart failure? Eur Heart J. 2000; 21 (22): 1822-4.</mixed-citation>
        <element-citation publication-type="journal">
          <article-title>The Tei index- a role in the diagnosis of heart failure?</article-title>
          <source>Eur Heart J</source>
          <date>
            <year>2000</year>
          </date>
          <fpage>1822</fpage>
          <lpage>4</lpage>
          <issue>22</issue>
          <volume>21</volume>
          <person-group person-group-type="author">
            <name>
              <surname>St John Sutton</surname>
              <given-names>M</given-names>
            </name>
            <name>
              <surname>Wiegers</surname>
              <given-names>SE</given-names>
            </name>
          </person-group>
        </element-citation>
      </ref>
      <ref id="B6">
        <mixed-citation>6. Moller JE, Sondergaard E, Poulsen SH, Egstrup    K. The Doppler echocardiographic myocardial performance index predicts left-ventricular    dilation and cardiac death after myocardial infarction. Cardiology. 2001; 95:    105-11.</mixed-citation>
        <element-citation publication-type="journal">
          <article-title>The Doppler echocardiographic myocardial performance index predicts left-ventricular dilation and cardiac death after myocardial infarction</article-title>
          <source>Cardiology</source>
          <date>
            <year>2001</year>
          </date>
          <fpage>105</fpage>
          <lpage>11</lpage>
          <volume>95</volume>
          <person-group person-group-type="author">
            <name>
              <surname>Moller</surname>
              <given-names>JE</given-names>
            </name>
            <name>
              <surname>Sondergaard</surname>
              <given-names>E</given-names>
            </name>
            <name>
              <surname>Poulsen</surname>
              <given-names>SH</given-names>
            </name>
            <name>
              <surname>Egstrup</surname>
              <given-names>K</given-names>
            </name>
          </person-group>
        </element-citation>
      </ref>
      <ref id="B7">
        <label>7</label>
        <mixed-citation>7. New York Heart Association (NYHA). Nomenclarute and criteria for diagnosis of disease of the heart and great vessels. 7th ed. Boston: Little and Brown Company; 1973. p. 286.</mixed-citation>
        <element-citation publication-type="book">
          <source>Nomenclarute and criteria for diagnosis of disease of the heart and great vessels</source>
          <date>
            <year>1973</year>
          </date>
          <fpage>286</fpage>
        </element-citation>
      </ref>
      <ref id="B8">
        <mixed-citation>8. Weber KT, Kinasewitz GT, Janicki JS, Fishman    AP. Oxygen utilization and ventilation during exercise in patients with chronic    cardiac failure. Circulation. 1982; 65: 1213-23.</mixed-citation>
        <element-citation publication-type="journal">
          <article-title>Oxygen utilization and ventilation during exercise in patients with chronic cardiac failure</article-title>
          <source>Circulation</source>
          <date>
            <year>1982</year>
          </date>
          <fpage>1213</fpage>
          <lpage>23</lpage>
          <volume>65</volume>
          <person-group person-group-type="author">
            <name>
              <surname>Weber</surname>
              <given-names>KT</given-names>
            </name>
            <name>
              <surname>Kinasewitz</surname>
              <given-names>GT</given-names>
            </name>
            <name>
              <surname>Janicki</surname>
              <given-names>JS</given-names>
            </name>
            <name>
              <surname>Fishman</surname>
              <given-names>AP</given-names>
            </name>
          </person-group>
        </element-citation>
      </ref>
      <ref id="B9">
        <mixed-citation>9. Mancini DM, Eisen H, Kussmaul W, Mull R, Edmunds    LH Jr, Wilson JR. Value of peak exercise oxygen consumption for optimal timing    of cardiac transplantation in ambulatory patients with heart failure. Circulation.    1991; 83: 778-86.</mixed-citation>
        <element-citation publication-type="journal">
          <article-title>Value of peak exercise oxygen consumption for optimal timing of cardiac transplantation in ambulatory patients with heart failure</article-title>
          <source>Circulation</source>
          <date>
            <year>1991</year>
          </date>
          <fpage>778</fpage>
          <lpage>86</lpage>
          <volume>83</volume>
          <person-group person-group-type="author">
            <name>
              <surname>Mancini</surname>
              <given-names>DM</given-names>
            </name>
            <name>
              <surname>Eisen</surname>
              <given-names>H</given-names>
            </name>
            <name>
              <surname>Kussmaul</surname>
              <given-names>W</given-names>
            </name>
            <name>
              <surname>Mull</surname>
              <given-names>R</given-names>
            </name>
            <name>
              <surname>Edmunds Jr</surname>
              <given-names>LH</given-names>
            </name>
            <name>
              <surname>Wilson</surname>
              <given-names>JR</given-names>
            </name>
          </person-group>
        </element-citation>
      </ref>
      <ref id="B10">
        <mixed-citation>10. Riley M, McFarland J, Stanford CF, Nicholls    DP. Oxygen consumption during corridor walk testing in chronic heart failure.    Eur Heart J. 1992; 13: 789-93.</mixed-citation>
        <element-citation publication-type="journal">
          <article-title>Oxygen consumption during corridor walk testing in chronic heart failure</article-title>
          <source>Eur Heart J</source>
          <date>
            <year>1992</year>
          </date>
          <fpage>789</fpage>
          <lpage>93</lpage>
          <volume>13</volume>
          <person-group person-group-type="author">
            <name>
              <surname>Riley</surname>
              <given-names>M</given-names>
            </name>
            <name>
              <surname>McFarland</surname>
              <given-names>J</given-names>
            </name>
            <name>
              <surname>Stanford</surname>
              <given-names>CF</given-names>
            </name>
            <name>
              <surname>Nicholls</surname>
              <given-names>DP</given-names>
            </name>
          </person-group>
        </element-citation>
      </ref>
      <ref id="B11">
        <mixed-citation>11. Guyatt GH, Sullivan MJ, Thompson PJ, Fallen    EL, Pugsley SO, Taylor DW, et al. The 6-minute walk test: a new measure of exercise    capacity in patients with chronic heart failure. Can Med Assoc J. 1985; 132:    919-23.</mixed-citation>
        <element-citation publication-type="journal">
          <article-title>The 6-minute walk test: a new measure of exercise capacity in patients with chronic heart failure</article-title>
          <source>Can Med Assoc J</source>
          <date>
            <year>1985</year>
          </date>
          <fpage>919</fpage>
          <lpage>23</lpage>
          <volume>132</volume>
          <person-group person-group-type="author">
            <name>
              <surname>Guyatt</surname>
              <given-names>GH</given-names>
            </name>
            <name>
              <surname>Sullivan</surname>
              <given-names>MJ</given-names>
            </name>
            <name>
              <surname>Thompson</surname>
              <given-names>PJ</given-names>
            </name>
            <name>
              <surname>Fallen</surname>
              <given-names>EL</given-names>
            </name>
            <name>
              <surname>Pugsley</surname>
              <given-names>SO</given-names>
            </name>
            <name>
              <surname>Taylor</surname>
              <given-names>DW</given-names>
            </name>
          </person-group>
        </element-citation>
      </ref>
      <ref id="B12">
        <mixed-citation>12. Guyatt GH, Thompson PJ, Berman LB, Sullivan    MJ, Townsend M, Jones NL, et al. How should we measyre function in patients    with chronic heart and lung disease? J Chronic Dis. 1985; 28: 517-24.</mixed-citation>
        <element-citation publication-type="journal">
          <article-title>How should we measyre function in patients with chronic heart and lung disease?</article-title>
          <source>J Chronic Dis</source>
          <date>
            <year>1985</year>
          </date>
          <fpage>517</fpage>
          <lpage>24</lpage>
          <volume>28</volume>
          <person-group person-group-type="author">
            <name>
              <surname>Guyatt</surname>
              <given-names>GH</given-names>
            </name>
            <name>
              <surname>Thompson</surname>
              <given-names>PJ</given-names>
            </name>
            <name>
              <surname>Berman</surname>
              <given-names>LB</given-names>
            </name>
            <name>
              <surname>Sullivan</surname>
              <given-names>MJ</given-names>
            </name>
            <name>
              <surname>Townsend</surname>
              <given-names>M</given-names>
            </name>
            <name>
              <surname>Jones</surname>
              <given-names>NL</given-names>
            </name>
          </person-group>
        </element-citation>
      </ref>
      <ref id="B13">
        <mixed-citation>13. Lipkin DP, Scriven AJ, Crake T, Poole-Wilson    PA. Six minute walking test for assessing exercise capacity in chronic heart    failure. Br Med J (Clin Res Ed.). 1986; 292: 653-5.</mixed-citation>
        <element-citation publication-type="journal">
          <article-title>Six minute walking test for assessing exercise capacity in chronic heart failure</article-title>
          <source>Br Med J (Clin Res Ed.)</source>
          <date>
            <year>1986</year>
          </date>
          <fpage>653</fpage>
          <lpage>5</lpage>
          <volume>292</volume>
          <person-group person-group-type="author">
            <name>
              <surname>Lipkin</surname>
              <given-names>DP</given-names>
            </name>
            <name>
              <surname>Scriven</surname>
              <given-names>AJ</given-names>
            </name>
            <name>
              <surname>Crake</surname>
              <given-names>T</given-names>
            </name>
            <name>
              <surname>Poole-Wilson</surname>
              <given-names>PA</given-names>
            </name>
          </person-group>
        </element-citation>
      </ref>
      <ref id="B14">
        <mixed-citation>14. Dracup K, Walden JA, Stevenson LW, Brecht    ML. Quality of life in patients with advanced heart failure. J Heart and Lung    Transplant. 1992; 11: 273-9.</mixed-citation>
        <element-citation publication-type="journal">
          <article-title>Quality of life in patients with advanced heart failure</article-title>
          <source>J Heart and Lung Transplant</source>
          <date>
            <year>1992</year>
          </date>
          <fpage>273</fpage>
          <lpage>9</lpage>
          <volume>11</volume>
          <person-group person-group-type="author">
            <name>
              <surname>Dracup</surname>
              <given-names>K</given-names>
            </name>
            <name>
              <surname>Walden</surname>
              <given-names>JA</given-names>
            </name>
            <name>
              <surname>Stevenson</surname>
              <given-names>LW</given-names>
            </name>
            <name>
              <surname>Brecht</surname>
              <given-names>ML</given-names>
            </name>
          </person-group>
        </element-citation>
      </ref>
      <ref id="B15">
        <mixed-citation>15. Packer M, Gheorghiade M, Young JB, Constantini    PJ, Adams KF, Cody RJ, et al. for the RADIANCE Study. Withdrawal of digoxin    from patients with chronic heart failure treated with angiotensin converting    enzyme inhibitors. N Engl J Med. 1993; 329: 1-7.</mixed-citation>
        <element-citation publication-type="journal">
          <article-title>Withdrawal of digoxin from patients with chronic heart failure treated with angiotensin converting enzyme inhibitors</article-title>
          <source>N Engl J Med</source>
          <date>
            <year>1993</year>
          </date>
          <fpage>1</fpage>
          <lpage>7</lpage>
          <volume>329</volume>
          <person-group person-group-type="author">
            <name>
              <surname>Packer</surname>
              <given-names>M</given-names>
            </name>
            <name>
              <surname>Gheorghiade</surname>
              <given-names>M</given-names>
            </name>
            <name>
              <surname>Young</surname>
              <given-names>JB</given-names>
            </name>
            <name>
              <surname>Constantini</surname>
              <given-names>PJ</given-names>
            </name>
            <name>
              <surname>Adams</surname>
              <given-names>KF</given-names>
            </name>
            <name>
              <surname>Cody</surname>
              <given-names>RJ</given-names>
            </name>
          </person-group>
        </element-citation>
      </ref>
      <ref id="B16">
        <mixed-citation>16. Uretsky BF, Young JB, Shahidi E, Yellen LG,    Harrison MC, Jolly MK on behalf of the PROVED Investigative Group. Randomized    study assessing the effect of digoxin withdrawal in patients with mild to moderate    chronic congestive heart failure: results of the PROVED Trial. J Am Coll Cardiol.    1993; 22: 955-62.</mixed-citation>
        <element-citation publication-type="journal">
          <article-title>Randomized study assessing the effect of digoxin withdrawal in patients with mild to moderate chronic congestive heart failure: results of the PROVED Trial</article-title>
          <source>J Am Coll Cardiol</source>
          <date>
            <year>1993</year>
          </date>
          <fpage>955</fpage>
          <lpage>62</lpage>
          <volume>22</volume>
          <person-group person-group-type="author">
            <name>
              <surname>Uretsky</surname>
              <given-names>BF</given-names>
            </name>
            <name>
              <surname>Young</surname>
              <given-names>JB</given-names>
            </name>
            <name>
              <surname>Shahidi</surname>
              <given-names>E</given-names>
            </name>
            <name>
              <surname>Yellen</surname>
              <given-names>LG</given-names>
            </name>
            <name>
              <surname>Harrison</surname>
              <given-names>MC</given-names>
            </name>
            <name>
              <surname>Jolly</surname>
              <given-names>MK</given-names>
            </name>
          </person-group>
        </element-citation>
      </ref>
      <ref id="B17">
        <mixed-citation>17. Califf RM, Adams KF, McKenna WJ, Gheorghiade    M, Uretsky BF, McNulty SE, etal. A randomized trial of epoprostenol therapy    for severe congestive heart failure: The Flolan International Randomized Survival    Trial (FIRST). Am Heart J. 1997; 134: 44-54.</mixed-citation>
        <element-citation publication-type="journal">
          <article-title>A randomized trial of epoprostenol therapy for severe congestive heart failure: The Flolan International Randomized Survival Trial (FIRST)</article-title>
          <source>Am Heart J</source>
          <date>
            <year>1997</year>
          </date>
          <fpage>44</fpage>
          <lpage>54</lpage>
          <volume>134</volume>
          <person-group person-group-type="author">
            <name>
              <surname>Califf</surname>
              <given-names>RM</given-names>
            </name>
            <name>
              <surname>Adams</surname>
              <given-names>KF</given-names>
            </name>
            <name>
              <surname>McKenna</surname>
              <given-names>WJ</given-names>
            </name>
            <name>
              <surname>Gheorghiade</surname>
              <given-names>M</given-names>
            </name>
            <name>
              <surname>Uretsky</surname>
              <given-names>BF</given-names>
            </name>
            <name>
              <surname>McNulty</surname>
              <given-names>SE</given-names>
            </name>
          </person-group>
        </element-citation>
      </ref>
      <ref id="B18">
        <mixed-citation>18. Effects of carvedilol, a vasodilator beta-bocker,    in patients with congestive heart failure due to ischemic heart disease. Australia     New Zealand Heart Failure Research. Circulation. 1995; 92: 212-8.</mixed-citation>
        <element-citation publication-type="journal">
          <article-title>Effects of carvedilol, a vasodilator beta-bocker, in patients with congestive heart failure due to ischemic heart disease: Australia - New Zealand Heart Failure Research</article-title>
          <source>Circulation</source>
          <date>
            <year>1995</year>
          </date>
          <fpage>212</fpage>
          <lpage>8</lpage>
          <volume>92</volume>
        </element-citation>
      </ref>
      <ref id="B19">
        <mixed-citation>19. Packer M, Bristow ML, Cohn JN, Colucci WS,    Fowler MB, Gilbert EM, et al. The effect of carvedilol on morbidity and mortality    in patients with chronic heart failure. US Carvedilol Heart Failure Study Groups.    N Engl J Med. 1996; 334: 1349-55.</mixed-citation>
        <element-citation publication-type="journal">
          <article-title>The effect of carvedilol on morbidity and mortality in patients with chronic heart failure: US Carvedilol Heart Failure Study Groups</article-title>
          <source>N Engl J Med</source>
          <date>
            <year>1996</year>
          </date>
          <fpage>1349</fpage>
          <lpage>55</lpage>
          <volume>334</volume>
          <person-group person-group-type="author">
            <name>
              <surname>Packer</surname>
              <given-names>M</given-names>
            </name>
            <name>
              <surname>Bristow</surname>
              <given-names>ML</given-names>
            </name>
            <name>
              <surname>Cohn</surname>
              <given-names>JN</given-names>
            </name>
            <name>
              <surname>Colucci</surname>
              <given-names>WS</given-names>
            </name>
            <name>
              <surname>Fowler</surname>
              <given-names>MB</given-names>
            </name>
            <name>
              <surname>Gilbert</surname>
              <given-names>EM</given-names>
            </name>
          </person-group>
        </element-citation>
      </ref>
      <ref id="B20">
        <mixed-citation>20. Metra M, Nardi M, Giubbini R, Dei Cas L.    Effects of short and long-term carvedilol administration on rest and exercise    hemodynamic variables, exercise capacity and clinical conditions in patients    with idiopathic dilated cardiomyopathy. J Am Coll Cardiol. 1994; 24: 1678-87.</mixed-citation>
        <element-citation publication-type="journal">
          <article-title>Effects of short and long-term carvedilol administration on rest and exercise hemodynamic variables, exercise capacity and clinical conditions in patients with idiopathic dilated cardiomyopathy</article-title>
          <source>J Am Coll Cardiol</source>
          <date>
            <year>1994</year>
          </date>
          <fpage>1678</fpage>
          <lpage>87</lpage>
          <volume>24</volume>
          <person-group person-group-type="author">
            <name>
              <surname>Metra</surname>
              <given-names>M</given-names>
            </name>
            <name>
              <surname>Nardi</surname>
              <given-names>M</given-names>
            </name>
            <name>
              <surname>Giubbini</surname>
              <given-names>R</given-names>
            </name>
            <name>
              <surname>Dei Cas</surname>
              <given-names>L</given-names>
            </name>
          </person-group>
        </element-citation>
      </ref>
      <ref id="B21">
        <mixed-citation>21. Krum H, Sackner-Bernstein JD, Goldsmith RL,    Kurkin ML, Schuwartz B, Penn J, et al. Doubleblind, placebo-controlled study    of the long-term efficacy of carvedilol in severe chronic heart failure. Circulation.    1995; 92: 1499-506.</mixed-citation>
        <element-citation publication-type="journal">
          <article-title>Doubleblind, placebo-controlled study of the long-term efficacy of carvedilol in severe chronic heart failure</article-title>
          <source>Circulation</source>
          <date>
            <year>1995</year>
          </date>
          <fpage>1499</fpage>
          <lpage>506</lpage>
          <volume>92</volume>
          <person-group person-group-type="author">
            <name>
              <surname>Krum</surname>
              <given-names>H</given-names>
            </name>
            <name>
              <surname>Sackner-Bernstein</surname>
              <given-names>JD</given-names>
            </name>
            <name>
              <surname>Goldsmith</surname>
              <given-names>RL</given-names>
            </name>
            <name>
              <surname>Kurkin</surname>
              <given-names>ML</given-names>
            </name>
            <name>
              <surname>Schuwartz</surname>
              <given-names>B</given-names>
            </name>
            <name>
              <surname>Penn</surname>
              <given-names>J</given-names>
            </name>
          </person-group>
        </element-citation>
      </ref>
      <ref id="B22">
        <mixed-citation>22. Olsen SL, Gilbert EM, Renlund DG, Taylor    DO, Yanowitz FD, Bristow MR. Carvedilol improves left ventricular function and    symptoms in chronic heart failure: a double-blind randomized study. J Am Coll    Cardiol. 1995; 25: 1225-31.</mixed-citation>
        <element-citation publication-type="journal">
          <article-title>Carvedilol improves left ventricular function and symptoms in chronic heart failure: a double-blind randomized study</article-title>
          <source>J Am Coll Cardiol</source>
          <date>
            <year>1995</year>
          </date>
          <fpage>1225</fpage>
          <lpage>31</lpage>
          <volume>25</volume>
          <person-group person-group-type="author">
            <name>
              <surname>Olsen</surname>
              <given-names>SL</given-names>
            </name>
            <name>
              <surname>Gilbert</surname>
              <given-names>EM</given-names>
            </name>
            <name>
              <surname>Renlund</surname>
              <given-names>DG</given-names>
            </name>
            <name>
              <surname>Taylor</surname>
              <given-names>DO</given-names>
            </name>
            <name>
              <surname>Yanowitz</surname>
              <given-names>FD</given-names>
            </name>
            <name>
              <surname>Bristow</surname>
              <given-names>MR</given-names>
            </name>
          </person-group>
        </element-citation>
      </ref>
      <ref id="B23">
        <mixed-citation>23. Meyer K, Scwaibold M, Westbrooh S, Beneke    R, Hajric R, Lehmann M, et al. Effects of exercise training and activity restriction    on 6-minute walking test performance in patients with chronic heart failure.    Am Heart J. 1997; 133: 447-53.</mixed-citation>
        <element-citation publication-type="journal">
          <article-title>Effects of exercise training and activity restriction on 6-minute walking test performance in patients with chronic heart failure</article-title>
          <source>Am Heart J</source>
          <date>
            <year>1997</year>
          </date>
          <fpage>447</fpage>
          <lpage>53</lpage>
          <volume>133</volume>
          <person-group person-group-type="author">
            <name>
              <surname>Meyer</surname>
              <given-names>K</given-names>
            </name>
            <name>
              <surname>Scwaibold</surname>
              <given-names>M</given-names>
            </name>
            <name>
              <surname>Westbrooh</surname>
              <given-names>S</given-names>
            </name>
            <name>
              <surname>Beneke</surname>
              <given-names>R</given-names>
            </name>
            <name>
              <surname>Hajric</surname>
              <given-names>R</given-names>
            </name>
            <name>
              <surname>Lehmann</surname>
              <given-names>M</given-names>
            </name>
          </person-group>
        </element-citation>
      </ref>
      <ref id="B24">
        <mixed-citation>24. Bittner V, Weiner D, Yusuf S, Rogers WJ,    McIntyre KM, Bangdiwala SI, et al. for the SOLVD Investigators. Prediction of    mortality and morbidity with a 6-minute walk test in patients with left ventricular    dysfunction. JAMA. 1993; 270: 1702-7.</mixed-citation>
        <element-citation publication-type="journal">
          <article-title>Prediction of mortality and morbidity with a 6-minute walk test in patients with left ventricular dysfunction</article-title>
          <source>JAMA</source>
          <date>
            <year>1993</year>
          </date>
          <fpage>1702</fpage>
          <lpage>7</lpage>
          <volume>270</volume>
          <person-group person-group-type="author">
            <name>
              <surname>Bittner</surname>
              <given-names>V</given-names>
            </name>
            <name>
              <surname>Weiner</surname>
              <given-names>D</given-names>
            </name>
            <name>
              <surname>Yusuf</surname>
              <given-names>S</given-names>
            </name>
            <name>
              <surname>Rogers</surname>
              <given-names>WJ</given-names>
            </name>
            <name>
              <surname>McIntyre</surname>
              <given-names>KM</given-names>
            </name>
            <name>
              <surname>Bangdiwala</surname>
              <given-names>SI</given-names>
            </name>
          </person-group>
        </element-citation>
      </ref>
      <ref id="B25">
        <mixed-citation>25. Cahalin L, Mathier M, Semigran M, Dec W,    DiSalvo T. The six-minute walk test predicts peak oxygen uptake and survival    in patients with advanced heart failure. Chest. 1996; 110: 325-32.</mixed-citation>
        <element-citation publication-type="journal">
          <article-title>The six-minute walk test predicts peak oxygen uptake and survival in patients with advanced heart failure</article-title>
          <source>Chest</source>
          <date>
            <year>1996</year>
          </date>
          <fpage>325</fpage>
          <lpage>32</lpage>
          <volume>110</volume>
          <person-group person-group-type="author">
            <name>
              <surname>Cahalin</surname>
              <given-names>L</given-names>
            </name>
            <name>
              <surname>Mathier</surname>
              <given-names>M</given-names>
            </name>
            <name>
              <surname>Semigran</surname>
              <given-names>M</given-names>
            </name>
            <name>
              <surname>Dec</surname>
              <given-names>W</given-names>
            </name>
            <name>
              <surname>DiSalvo</surname>
              <given-names>T</given-names>
            </name>
          </person-group>
        </element-citation>
      </ref>
      <ref id="B26">
        <mixed-citation>26. Roul G, Germain P, Bareiss P. Does the 6-minute    walk test predict the prognosis in patients with NYHA class II or III chronic    heart failure? Am Heart J. 1998; 136: 449-57.</mixed-citation>
        <element-citation publication-type="journal">
          <article-title>Does the 6-minute walk test predict the prognosis in patients with NYHA class II or III chronic heart failure?</article-title>
          <source>Am Heart J</source>
          <date>
            <year>1998</year>
          </date>
          <fpage>449</fpage>
          <lpage>57</lpage>
          <volume>136</volume>
          <person-group person-group-type="author">
            <name>
              <surname>Roul</surname>
              <given-names>G</given-names>
            </name>
            <name>
              <surname>Germain</surname>
              <given-names>P</given-names>
            </name>
            <name>
              <surname>Bareiss</surname>
              <given-names>P</given-names>
            </name>
          </person-group>
        </element-citation>
      </ref>
      <ref id="B27">
        <mixed-citation>27. Swedberg K, Califf RM, Adams K. FIRST Investigators.    Six minute walk test gives prognostic information in severe heart failure. J    Am Coll Cardiol. 1995; 25: 329A.</mixed-citation>
        <element-citation publication-type="journal">
          <article-title>FIRST Investigators: Six minute walk test gives prognostic information in severe heart failure</article-title>
          <source>J Am Coll Cardiol</source>
          <date>
            <year>1995</year>
          </date>
          <fpage>329A</fpage>
          <volume>25</volume>
          <person-group person-group-type="author">
            <name>
              <surname>Swedberg</surname>
              <given-names>K</given-names>
            </name>
            <name>
              <surname>Califf</surname>
              <given-names>RM</given-names>
            </name>
            <name>
              <surname>Adams</surname>
              <given-names>K</given-names>
            </name>
          </person-group>
        </element-citation>
      </ref>
      <ref id="B28">
        <mixed-citation>28. Zugck C, Kruger C, Durr S, Gerber SH. Is    the 6-minute walking test a reliable substitute for peak oxygen uptake in patients    with dilated cardiomyopathy? Eur Heart J. 2000; 21: 540-9.</mixed-citation>
        <element-citation publication-type="journal">
          <article-title>Is the 6-minute walking test a reliable substitute for peak oxygen uptake in patients with dilated cardiomyopathy?</article-title>
          <source>Eur Heart J</source>
          <date>
            <year>2000</year>
          </date>
          <fpage>540</fpage>
          <lpage>9</lpage>
          <volume>21</volume>
          <person-group person-group-type="author">
            <name>
              <surname>Zugck</surname>
              <given-names>C</given-names>
            </name>
            <name>
              <surname>Kruger</surname>
              <given-names>C</given-names>
            </name>
            <name>
              <surname>Durr</surname>
              <given-names>S</given-names>
            </name>
            <name>
              <surname>Gerber</surname>
              <given-names>SH</given-names>
            </name>
          </person-group>
        </element-citation>
      </ref>
      <ref id="B29">
        <mixed-citation>29. Lucas C, Stevenson LW, Johnson W, Hartley    H, Hamilton MA, Walden J, et al. The 6-min walk and peak oxygen consumption    in advanced heart failure: aerobic capacity and survival. Am Heart J. 1999;    138: 618-24.</mixed-citation>
        <element-citation publication-type="journal">
          <article-title>The 6-min walk and peak oxygen consumption in advanced heart failure: aerobic capacity and survival</article-title>
          <source>Am Heart J</source>
          <date>
            <year>1999</year>
          </date>
          <fpage>618</fpage>
          <lpage>24</lpage>
          <volume>138</volume>
          <person-group person-group-type="author">
            <name>
              <surname>Lucas</surname>
              <given-names>C</given-names>
            </name>
            <name>
              <surname>Stevenson</surname>
              <given-names>LW</given-names>
            </name>
            <name>
              <surname>Johnson</surname>
              <given-names>W</given-names>
            </name>
            <name>
              <surname>Hartley</surname>
              <given-names>H</given-names>
            </name>
            <name>
              <surname>Hamilton</surname>
              <given-names>MA</given-names>
            </name>
            <name>
              <surname>Walden</surname>
              <given-names>J</given-names>
            </name>
          </person-group>
        </element-citation>
      </ref>
      <ref id="B30">
        <mixed-citation>30. Tei C, Ling LH, Hodge DO, Bailey KR, Oh JK,    Rodeheffer RJ, et al. New index of combined systolic and diastolic myocardial    performance: a simple and reproducible measure of cardiac function- a study    in normal and dilated cardiomyopathy. J Cardiol. 1995; 26 (6): 357-66.</mixed-citation>
        <element-citation publication-type="journal">
          <article-title>New index of combined systolic and diastolic myocardial performance: a simple and reproducible measure of cardiac function- a study in normal and dilated cardiomyopathy</article-title>
          <source>J Cardiol</source>
          <date>
            <year>1995</year>
          </date>
          <fpage>357</fpage>
          <lpage>66</lpage>
          <issue>6</issue>
          <volume>26</volume>
          <person-group person-group-type="author">
            <name>
              <surname>Tei</surname>
              <given-names>C</given-names>
            </name>
            <name>
              <surname>Ling</surname>
              <given-names>LH</given-names>
            </name>
            <name>
              <surname>Hodge</surname>
              <given-names>DO</given-names>
            </name>
            <name>
              <surname>Bailey</surname>
              <given-names>KR</given-names>
            </name>
            <name>
              <surname>Oh</surname>
              <given-names>JK</given-names>
            </name>
            <name>
              <surname>Rodeheffer</surname>
              <given-names>RJ</given-names>
            </name>
          </person-group>
        </element-citation>
      </ref>
      <ref id="B31">
        <mixed-citation>31. Zoghbi WA, Enriquez-Sarano M, Foster E, Grayburn    PA, Kraft CD, Levine RA, et al. American Society of Echocardiography. Recommendations    for evaluation of the severity of native valvular regurgitation with two-dimensional    and Doppler echocardiography. J Am Soc Echocardiogr. 2003; 16: 777-802.</mixed-citation>
        <element-citation publication-type="journal">
          <article-title>American Society of Echocardiography: Recommendations for evaluation of the severity of native valvular regurgitation with two-dimensional and Doppler echocardiography</article-title>
          <source>J Am Soc Echocardiogr</source>
          <date>
            <year>2003</year>
          </date>
          <fpage>777</fpage>
          <lpage>802</lpage>
          <volume>16</volume>
          <person-group person-group-type="author">
            <name>
              <surname>Zoghbi</surname>
              <given-names>WA</given-names>
            </name>
            <name>
              <surname>Enriquez-Sarano</surname>
              <given-names>M</given-names>
            </name>
            <name>
              <surname>Foster</surname>
              <given-names>E</given-names>
            </name>
            <name>
              <surname>Grayburn</surname>
              <given-names>PA</given-names>
            </name>
            <name>
              <surname>Kraft</surname>
              <given-names>CD</given-names>
            </name>
            <name>
              <surname>Levine</surname>
              <given-names>RA</given-names>
            </name>
          </person-group>
        </element-citation>
      </ref>
      <ref id="B32">
        <mixed-citation>32. McGavin CR, Gupta SP, McHardy GJ. Twelve-minute    walking test for assessing disability in chronic bronchitis. Br Med J. 1976;    1: 822-3.</mixed-citation>
        <element-citation publication-type="journal">
          <article-title>Twelve-minute walking test for assessing disability in chronic bronchitis</article-title>
          <source>Br Med J</source>
          <date>
            <year>1976</year>
          </date>
          <fpage>822</fpage>
          <lpage>3</lpage>
          <volume>1</volume>
          <person-group person-group-type="author">
            <name>
              <surname>McGavin</surname>
              <given-names>CR</given-names>
            </name>
            <name>
              <surname>Gupta</surname>
              <given-names>SP</given-names>
            </name>
            <name>
              <surname>McHardy</surname>
              <given-names>GJ</given-names>
            </name>
          </person-group>
        </element-citation>
      </ref>
      <ref id="B33">
        <mixed-citation>33. Butland RJ, Pang J, Gross ER, Woodcock AA,    Geddes DM. Two-, six-, and 12-minute walking tests in respiratory disease. Br    Med J. 1982; 284: 1607-8.</mixed-citation>
        <element-citation publication-type="journal">
          <article-title>Two-, six-, and 12-minute walking tests in respiratory disease</article-title>
          <source>Br Med J</source>
          <date>
            <year>1982</year>
          </date>
          <fpage>1607</fpage>
          <lpage>8</lpage>
          <volume>284</volume>
          <person-group person-group-type="author">
            <name>
              <surname>Butland</surname>
              <given-names>RJ</given-names>
            </name>
            <name>
              <surname>Pang</surname>
              <given-names>J</given-names>
            </name>
            <name>
              <surname>Gross</surname>
              <given-names>ER</given-names>
            </name>
            <name>
              <surname>Woodcock</surname>
              <given-names>AA</given-names>
            </name>
            <name>
              <surname>Geddes</surname>
              <given-names>DM</given-names>
            </name>
          </person-group>
        </element-citation>
      </ref>
      <ref id="B34">
        <mixed-citation>34. Zugck C, Kruger C, Durr S, Gerber SH, Haunstetter    A, Hornig K, et al. Is the 6-minute walk test a reliable substitute for peak    oxygen uptake in patients with dilated cardiomyopathy? Eur Heart J. 2000; 21:    540-9.</mixed-citation>
        <element-citation publication-type="journal">
          <article-title>Is the 6-minute walk test a reliable substitute for peak oxygen uptake in patients with dilated cardiomyopathy?</article-title>
          <source>Eur Heart J</source>
          <date>
            <year>2000</year>
          </date>
          <fpage>540</fpage>
          <lpage>9</lpage>
          <volume>21</volume>
          <person-group person-group-type="author">
            <name>
              <surname>Zugck</surname>
              <given-names>C</given-names>
            </name>
            <name>
              <surname>Kruger</surname>
              <given-names>C</given-names>
            </name>
            <name>
              <surname>Durr</surname>
              <given-names>S</given-names>
            </name>
            <name>
              <surname>Gerber</surname>
              <given-names>SH</given-names>
            </name>
            <name>
              <surname>Haunstetter</surname>
              <given-names>A</given-names>
            </name>
            <name>
              <surname>Hornig</surname>
              <given-names>K</given-names>
            </name>
          </person-group>
        </element-citation>
      </ref>
      <ref id="B35">
        <mixed-citation>35. Ingle L, Rigby AS, Nabb S, Jones PK, Clark    AL, Cleland JG. Clinical determinants of poor six-minute walk test performance    in patients with left ventricular systolic dysfunction and no major structural    heart disease. Eur J Heart Fail. 2006; 8 (3): 321-5.</mixed-citation>
        <element-citation publication-type="journal">
          <article-title>Clinical determinants of poor six-minute walk test performance in patients with left ventricular systolic dysfunction and no major structural heart disease</article-title>
          <source>Eur J Heart Fail</source>
          <date>
            <year>2006</year>
          </date>
          <fpage>321</fpage>
          <lpage>5</lpage>
          <issue>3</issue>
          <volume>8</volume>
          <person-group person-group-type="author">
            <name>
              <surname>Ingle</surname>
              <given-names>L</given-names>
            </name>
            <name>
              <surname>Rigby</surname>
              <given-names>AS</given-names>
            </name>
            <name>
              <surname>Nabb</surname>
              <given-names>S</given-names>
            </name>
            <name>
              <surname>Jones</surname>
              <given-names>PK</given-names>
            </name>
            <name>
              <surname>Clark</surname>
              <given-names>AL</given-names>
            </name>
            <name>
              <surname>Cleland</surname>
              <given-names>JG</given-names>
            </name>
          </person-group>
        </element-citation>
      </ref>
      <ref id="B36">
        <mixed-citation>36. Ingle L, Goode K, Rigby AS, Cleland JG, Clark    AL. Predicting peak oxygen uptake from 6-min walk test performance in male patients    with left ventricular systolic dysfunction. Eur J Heart Fail. 2006; 8 (2): 198-202.</mixed-citation>
        <element-citation publication-type="journal">
          <article-title>Predicting peak oxygen uptake from 6-min walk test performance in male patients with left ventricular systolic dysfunction</article-title>
          <source>Eur J Heart Fail</source>
          <date>
            <year>2006</year>
          </date>
          <fpage>198</fpage>
          <lpage>202</lpage>
          <issue>2</issue>
          <volume>8</volume>
          <person-group person-group-type="author">
            <name>
              <surname>Ingle</surname>
              <given-names>L</given-names>
            </name>
            <name>
              <surname>Goode</surname>
              <given-names>K</given-names>
            </name>
            <name>
              <surname>Rigby</surname>
              <given-names>AS</given-names>
            </name>
            <name>
              <surname>Cleland</surname>
              <given-names>JG</given-names>
            </name>
            <name>
              <surname>Clark</surname>
              <given-names>AL</given-names>
            </name>
          </person-group>
        </element-citation>
      </ref>
      <ref id="B37">
        <mixed-citation>37. Arslan S, Erol MK, Gundogdu F, Sevimli S,    Aksakal E, Senocak H, et al. Prognostic value of 6-minute walk test in stable    outpatients with heart failure. Tex Heart Inst J. 2007; 34 (2): 166-9.</mixed-citation>
        <element-citation publication-type="journal">
          <article-title>Prognostic value of 6-minute walk test in stable outpatients with heart failure</article-title>
          <source>Tex Heart Inst J</source>
          <date>
            <year>2007</year>
          </date>
          <fpage>166</fpage>
          <lpage>9</lpage>
          <issue>2</issue>
          <volume>34</volume>
          <person-group person-group-type="author">
            <name>
              <surname>Arslan</surname>
              <given-names>S</given-names>
            </name>
            <name>
              <surname>Erol</surname>
              <given-names>MK</given-names>
            </name>
            <name>
              <surname>Gundogdu</surname>
              <given-names>F</given-names>
            </name>
            <name>
              <surname>Sevimli</surname>
              <given-names>S</given-names>
            </name>
            <name>
              <surname>Aksakal</surname>
              <given-names>E</given-names>
            </name>
            <name>
              <surname>Senocak</surname>
              <given-names>H</given-names>
            </name>
          </person-group>
        </element-citation>
      </ref>
      <ref id="B38">
        <mixed-citation>38. Opasich C, Pinna GD, Mazza A, Febo O, Riccardi    R, Riccardi PG, et al. Six-minute walking performance in patients with moderate-to-severe    heart failure; is it a useful indicator in clinical practice? Eur Heart J. 2001;    22 (6): 488-96.</mixed-citation>
        <element-citation publication-type="journal">
          <article-title>Six-minute walking performance in patients with moderate-to-severe heart failure; is it a useful indicator in clinical practice?</article-title>
          <source>Eur Heart J</source>
          <date>
            <year>2001</year>
          </date>
          <fpage>488</fpage>
          <lpage>96</lpage>
          <issue>6</issue>
          <volume>22</volume>
          <person-group person-group-type="author">
            <name>
              <surname>Opasich</surname>
              <given-names>C</given-names>
            </name>
            <name>
              <surname>Pinna</surname>
              <given-names>GD</given-names>
            </name>
            <name>
              <surname>Mazza</surname>
              <given-names>A</given-names>
            </name>
            <name>
              <surname>Febo</surname>
              <given-names>O</given-names>
            </name>
            <name>
              <surname>Riccardi</surname>
              <given-names>R</given-names>
            </name>
            <name>
              <surname>Riccardi</surname>
              <given-names>PG</given-names>
            </name>
          </person-group>
        </element-citation>
      </ref>
      <ref id="B39">
        <mixed-citation>39. Hutcheon SD, Gillespie ND, Crombie IK, Struthers    AD, McMurdo MET. Perindopril improves six minute walking distance in controlled    trial dysfunction: a randomised double blind placebo older patients with left    ventricular systolic. Heart. 2002; 88: 373-7.</mixed-citation>
        <element-citation publication-type="journal">
          <article-title>Perindopril improves six minute walking distance in controlled trial dysfunction: a randomised double blind placebo older patients with left ventricular systolic</article-title>
          <source>Heart</source>
          <date>
            <year>2002</year>
          </date>
          <fpage>373</fpage>
          <lpage>7</lpage>
          <volume>88</volume>
          <person-group person-group-type="author">
            <name>
              <surname>Hutcheon</surname>
              <given-names>SD</given-names>
            </name>
            <name>
              <surname>Gillespie</surname>
              <given-names>ND</given-names>
            </name>
            <name>
              <surname>Crombie</surname>
              <given-names>IK</given-names>
            </name>
            <name>
              <surname>Struthers</surname>
              <given-names>AD</given-names>
            </name>
            <name>
              <surname>McMurdo</surname>
              <given-names>MET</given-names>
            </name>
          </person-group>
        </element-citation>
      </ref>
      <ref id="B40">
        <mixed-citation>40. Zi M, Carmichael N, Lye M. The effect of    Quinapril on functional status of elderly patients with diastolic heart failure.    Cardiovasc Drugs Ther. 2003; 17 (2): 133-9.</mixed-citation>
        <element-citation publication-type="journal">
          <article-title>The effect of Quinapril on functional status of elderly patients with diastolic heart failure</article-title>
          <source>Cardiovasc Drugs Ther</source>
          <date>
            <year>2003</year>
          </date>
          <fpage>133</fpage>
          <lpage>9</lpage>
          <issue>2</issue>
          <volume>17</volume>
          <person-group person-group-type="author">
            <name>
              <surname>Zi</surname>
              <given-names>M</given-names>
            </name>
            <name>
              <surname>Carmichael</surname>
              <given-names>N</given-names>
            </name>
            <name>
              <surname>Lye</surname>
              <given-names>M</given-names>
            </name>
          </person-group>
        </element-citation>
      </ref>
    </ref-list>
  </back>
  <sub-article article-type="translation" id="TRen" xml:lang="en">
    <front-stub>
      <article-categories>
        <subj-group subj-group-type="heading">
          <subject>Original Articles</subject>
        </subj-group>
      </article-categories>
      <title-group>
        <article-title xml:lang="en">chocardiography and 6-minute walk test in left ventricular systolic dysfunction</article-title>
      </title-group>
      <abstract xml:lang="en">
        <p>BACKGROUND: Chronic heart failure is a major cardiovascular disorder. OBJECTIVE: The aim of this study was to prospectively examine whether a 6-min walk test (6-MWT) result correlates with echocardiographic variables in patients with left ventricular systolic dysfunction and stable chronic heart failure. METHODS: We prospectively studied 52 patients (65% male; mean age 60&#177;11 years) who had chronic heart failure secondary to ischemic heart disease or idiopathic cardiomyopathy. All patients had left ventricular systolic dysfunction (ejection fraction &lt;0.45), and were in stable NYHA class II or III heart failure. An echo-Doppler study and a 6-MWT were performed on the same day. RESULTS: 6-MWT had moderate, but statistically significant correlation with end-systolic diameter (ESD) (r=-0.46; p=0.0006), with shortening fraction-SF (r=0.52; p=0.0001), and with ejection fraction-EF (r=0.5; p=0.0001), whereas it had poor, but statistically significant correlation with myocardial performance index-MPI (r=-0.39; p=0.0046), E/A(tricuspid) ratio (r=-0.333; p=0.016), pulmonary acceleration time (r=0.328; p=0.018), and lateral long axis amplitude (r=0.283; p=0.04). Linear regression model demonstrated that age (&#967;2=-0.59, p=&lt;0.001), restrictive transmitral filling pattern (&#967;2=-0.44, p=0.004) and left ventricular end-systolic dimension (&#967;2=-0.34, p=0.012) were independent factors that influenced the 6-MWT. CONCLUSION: In patients with heart failure due to left ventricular systolic dysfunction, the 6-MWT as a clinical assessment tool of the functional capacity has a significant correlation with the most important global LV systolic function parameters, as well as with LV MPI. In patients with LV systolic dysfunction, age, restrictive transmitral filling pattern, and left ventricular systolic dimension, were independently associated with the 6-MWT.</p>
      </abstract>
      <kwd-group xml:lang="en">
        <kwd>Heart failure</kwd>
        <kwd>echocardiography</kwd>
        <kwd>walking</kwd>
        <kwd>quality of life</kwd>
      </kwd-group>
    </front-stub>
    <body>
      <p>
        <bold> ORIGINAL ARTICLE</bold>
      </p>
      <p><undefined id="tx-body2"/>Echocardiography and 6-minute walk test in left ventricular systolic dysfunction</p>
      <p>
        <bold>Venera Berisha<sup>I</sup>; Gani Bajraktari<sup>I</sup>; Dritero Dobra<sup>II</sup>; Edmond Haliti<sup>I</sup>; Reshat Bajrami<sup>I</sup>; Shpend Elezi<sup>II</sup></bold>
      </p>
      <p><sup>I</sup>Second Division of Cardiology, Internal Medicine Clinic, University Clinical Center of Kosova, Prishtina - Kosovo</p>
      <p><sup>II</sup>Medical School, University of Prishtina, Prishtina - Kosovo</p>
      <p>Mailing address</p>
      <p>
        <bold>SUMMARY</bold>
      </p>
      <p><bold>BACKGROUND:</bold> Chronic heart failure is a major cardiovascular disorder.</p>
      <p><bold>OBJECTIVE:</bold> The aim of this study was to prospectively examine whether a 6-min walk test (6-MWT) result correlates with echocardiographic variables in patients with left ventricular systolic dysfunction and stable chronic heart failure.</p>
      <p><bold>METHODS:</bold> We prospectively studied 52 patients (65% male; mean age 60&#177;11 years) who had chronic heart failure secondary to ischemic heart disease or idiopathic cardiomyopathy. All patients had left ventricular systolic dysfunction (ejection fraction <underline>&lt;</underline>0.45), and were in stable NYHA class II or III heart failure. An echo-Doppler study and a 6-MWT were performed on the same day.</p>
      <p><bold>RESULTS:</bold> 6-MWT had moderate, but statistically significant correlation with end-systolic diameter (ESD) (r=-0.46; p=0.0006), with shortening fraction-SF (r=0.52; p=0.0001), and with ejection fraction-EF (r=0.5; p=0.0001), whereas it had poor, but statistically significant correlation with myocardial performance index-MPI (r=-0.39; p=0.0046), E/A(tricuspid) ratio (r=-0.333; p=0.016), pulmonary acceleration time (r=0.328; p=0.018), and lateral long axis amplitude (r=0.283; p=0.04). Linear regression model demonstrated that age (&#967;<sup>2</sup>=-0.59, p=&lt;0.001), restrictive transmitral filling pattern (&#967;<sup>2</sup>=-0.44, p=0.004) and left ventricular end-systolic dimension (&#967;<sup>2</sup>=-0.34, p=0.012) were independent factors that influenced the 6-MWT.</p>
      <p><bold>CONCLUSION:</bold> In patients with heart failure due to left ventricular systolic dysfunction, the 6-MWT as a clinical assessment tool of the functional capacity has a significant correlation with the most important global LV systolic function parameters, as well as with LV MPI. In patients with LV systolic dysfunction, age, restrictive transmitral filling pattern, and left ventricular systolic dimension, were independently associated with the 6-MWT. </p>
      <p><bold>Key words:</bold> Heart failure; echocardiography; walking, quality of life.</p>
      <p>
        <bold>Introduction</bold>
      </p>
      <p>Chronic heart failure is a major cardiovascular disorder with increasing incidence and prevalence<sup>1</sup>. Two-dimensional and Doppler echocardiography is a sensitive and noninvasive method of detecting cardiac abnormalities and systolic and/or diastolic dysfunction<sup>2</sup>. Variables of diastolic filling allow further identification of subgroups with divergent long-term prognoses<sup>3</sup>. Recently, myocardial performance index (MPI) has been suggested for the evaluation of ventricular function<sup>4</sup>. MPI is calculated from the pulsed Doppler recordings of ventricular inflow and outflow velocities, and thus combines both systolic and diastolic ventricular performance. It reflects global ventricular function and is less affected by localized segmental wall motion abnormalities, in addition to playing an important prognostic role in the diagnosis of heart failure<sup>5</sup> and in the prediction of cardiac events in patients with acute myocardial infarction<sup>6</sup>. The severity of congestive heart failure is usually graded according to patients' symptoms, in particular to the physical activity that induces dyspnea or fatigue. The NYHA functional heart failure classification meets only some of these criteria. However, the NYHA classification is based on the patient's self-assessment and its reliability is still a matter of debate<sup>7</sup>. The ideal instrument for risk stratification and optimal clinical management of congestive heart failure patients should be objective, as well as simple, inexpensive and safe. The peak oxygen uptake, measured during cardiopulmonary exercise testing is a more objective parameter to assess functional capacity and to predict survival in patients with heart failure<sup>8-10</sup>. However, this method is limited only to specialized centers, because it requires sophisticated equipment and specially trained personnel.</p>
      <p>The 6-min walk test (6-MWT) has been proposed as a simple and accurate alternative technique for measurement of submaximal exercise capacity in congestive heart failure patients<sup>11</sup>. It is considered to be realistically related to daily physical activity. Consequently, it has been incorporated into studies of assessment of exercise capacity<sup>12,13</sup>, of quality of life<sup>14</sup>, of efficacy of new therapeutic agents<sup>15-17</sup>, including beta-blockers<sup>18-22</sup>, of physical training programs<sup>23</sup> and of prognostic stratification<sup>24-29</sup>.</p>
      <p>The aim of the present study was to asses the relationship between 2-dimensional and Doppler echocardiographic parameters and 6-MWT in patients with heart failure and left ventricular systolic dysfunction. 6-MWT is used as a proxy measure of the quality of life; therefore, echocardiographic parameters that have independent association with 6-MWT would facilitate prediction of the quality of life. </p>
      <p>
        <bold>Methods</bold>
      </p>
      <p>
        <bold>Study population</bold>
      </p>
      <p>The study group included 52 patients with stable chronic heart failure secondary to ischemic heart disease or idiopathic cardiomyopathy, referred to the Second Division of Cardiology at the Internal Medicine Clinic of the University Clinical Center of Kosova, in Prishtina, Kosovo, between December 2005 and April 2007. </p>
      <p>The mean age was 60&#177;11 years. The cause of heart failure was idiopathic dilated cardiomyopathy in 19 patients and ischemic cardiomyopathy in 33 patients. All patients had an enlarged left ventricle (left ventricular [LV] diastolic dimension &gt;5.7cm) and global left ventricular systolic dysfunction (left ventricular ejection fraction [LVEF] &lt;0.45), and all were in stable New York Heart Association (NYHA) functional class II or III heart failure. The functional capacity of 27 patients was class II and that of the remaining 25 was class III. <xref ref-type="table" rid="tab01-body2">Table 1</xref> summarizes the patients' clinical and laboratory characteristics.</p>
      <table-wrap id="tab01-body2">
        <graphic xlink:href="1678-4170-abc-92-02-0127-00009-gt01-en.jpg"/></table-wrap>
      <p>Patients with rhythm disturbances (atrial fibrillation, serious ventricular arrhythmias), patients who had decompensated heart failure, limitation of physical activity due to factors other than exertional dyspnea and fatigue (such as arthritis), and those with moderate to severe renal failure, with chronic obstructive pulmonary disease were excluded from the study. We also excluded patients who had experienced unstable angina, acute myocardial infarction or stroke, anemia, and any febrile condition or infectious disease.</p>
      <p>The study was approved by the Institutional Ethics Committee and all patients gave their written informed consent. Standard medical therapy with e.g. ACE-inhibitors, beta-blockers, digoxin and diuretics was individually optimized based on symptoms and renal function at least 2 weeks prior to exercise testing. All patients continued to take their routine medication when the echocardiography and 6-MWT were performed.</p>
      <p>
        <bold>Data collection</bold>
      </p>
      <p>The history and physical examination was performed in all subjects. In all patients the routine biochemical measurements were performed: the measurements of erythrocytes, leucocytes, hemoglobin, hematocrit, erythrocyte sedimentation, BUN, creatinine, blood glucose, cholesterol, triglycerides and inflammatory blood analysis (fibrinogen, CRP). Measurements of weight, height, waist and hip were also performed.</p>
      <p>
        <bold>Echocardiographic examinations</bold>
      </p>
      <p>Echocardiographic examination was performed using a Philips Intelligent E-33 echocardiograph with a multi-frequency transducer, and harmonic imaging as appropriate. All echocardiographic studies were performed by the same investigator. The echocardiographic study was performed in the left lateral decubitus in the parasternal long-axis and 4-chamber views.</p>
      <p>The cross-sectional, two-dimensionally guided M mode recordings of LV short axis were performed using the left parasternal long axis view with the cursor at the tips of the mitral valve leaflets. Fractional shortening was calculated as the percentage fall in LV cavity dimension during systole in relation to that at end-diastole. Left ventricular ejection fraction was estimated using Simpson's biplane method. Left atrial dimension was measured from M-mode recordings with the cursor crossing the aortic root at the level of the aortic valve leaflets. LV long axis M-mode recordings were obtained with the cursor positioned at the lateral and septal angles of the mitral ring and right ventricular long axis recording with the cursor positioned at the lateral angle of the tricuspid ring. All M-mode recordings were zoomed to obtain better images for accurate measurements.</p>
      <p>Diastolic function of the left and right ventricles was assessed by pulsed Doppler. The pulsed Doppler sample volume was positioned at the tips of the mitral and tricuspid leaflets, respectively. We registered the E wave, A wave, from which the E/A ratio was calculated, and the deceleration time of E wave (DT-E). We also registered Er wave, Ar wave and Er/Ar ratio.</p>
      <p>The MPI was measured from mitral inflow and LV outflow velocity-time intervals as described by Tei et al<sup>30</sup>. The <italic>a</italic> interval measured from the cessation to the onset of mitral inflow is equal to the sum of isovolumetric contraction time (ICT), ejection time (ET), and isovolumetric relaxation time (IRT). Left ventricular ejection time <italic>b</italic> is the duration of left ventricular outflow velocity profile. Thus the sum of ICT and IRT was obtained by subtracting <italic>b</italic> from <italic>a</italic>. The index of combined LV systolic and diastolic function (the sum of ICT and IRT divided by ejection time) was calculated as (<italic>a</italic> - <italic>b</italic>) / <italic>b </italic>(<xref ref-type="fig" rid="fig01-body2">Fig.1</xref>). The IRT can be measured by subtracting the <italic>d</italic> interval, between the R wave and the cessation of LV outflow, from the<italic> c</italic> interval, between the R wave and the onset of mitral inflow. ICT was calculated by subtracting the IRT from <italic>a</italic>-<italic>b</italic>. </p>
      <fig id="fig01-body2">
        <graphic xlink:href="1678-4170-abc-92-02-0127-00009-gf01-en.jpg"/></fig>
      <p>Mitral regurgitation severity was assessed by color and continuous wave Doppler and was graded as mild, moderate, or severe according to the jet distance from the valve orifice and flow velocity profile, respectively, in line with the recommendations of the American Society of Echocardiography<sup>31</sup>. Likewise, tricuspid regurgitation was assessed by color flow and continuous-wave Doppler from the apical four-chamber view. Retrograde transtricuspid pressure drop &gt; 35 mmHg was taken as a sign of pulmonary hypertension when the right atrium was not dilated.</p>
      <p>
        <italic>
          <bold>6-min walk test</bold>
        </italic>
      </p>
      <p>Within 24 h of echocardiographic examination, a 6-MWT was performed on a level hallway surface; the test was administered by a registered nurse blinded to the results of echocardiography. According to the method of Gyatt et al<sup>11,12</sup> all patients were informed of the purpose, methods and use of the 6-min walk test results. The 6-MWT was conducted following a standardized protocol, between 10 am and 4 pm after usual medication<sup>11</sup>. A 15 m flat, obstacle-free corridor, with chairs placed at either end was used. Patients were instructed to walk as far as possible, turning 180&#186; every 15 m in the allotted time of 6 minutes. Patients walked unaccompanied so as not to influence walking speed, and they were asked to walk as far as possible within 6-minutes. Patients were permitted to rest, if needed, then they were told of the remaining time at every two minutes. At the end of the 6 min, the physician measured the total distance walked by the patient.</p>
      <p>
        <bold>Statistical analysis</bold>
      </p>
      <p>Data are presented as mean &#177; SD or proportions (% of patients). Continuous data are compared with two-tailed unpaired Student's t test. Discrete data are compared with chi- square test. Correlation between variables was performed using Pearson's correlation test. A p value &lt; 0.05 was considered to indicate statistical significance. Multivariate analysis was performed using linear regression model. Factors included in this model were age, restrictive transmitral filling pattern, left ventricular systolic dimension, myocardial performance index and diabetes mellitus. </p>
      <p>
        <bold>Results</bold>
      </p>
      <p>The clinical and laboratory characteristics of the 52 patients enrolled in the study are shown in <xref ref-type="table" rid="tab01-body2">Table 1</xref>, and the echocardiographic and Doppler measurements are shown in <xref ref-type="table" rid="tab02-body2">Table 2</xref>. There was a moderate, but statistically significant correlation of 6-MWT with LV posterior wall thickness ( r= 0.49; p&lt;0.001), left ventricular end-systolic dimension (r=-0.46, p&lt;0.001, <xref ref-type="fig" rid="fig02-body2">Fig.2</xref>), LV fractional shortening (r = 0.517, p&lt;0.001, <xref ref-type="fig" rid="fig03-body2">Fig. 3</xref>), and LVEF (r = 0.50, p&lt;0.001), whereas there was a poor, but statistically significant correlation with myocardial performance index-MPI (r=-0.39; p=0.0046, <xref ref-type="fig" rid="fig04-body2">Fig. 4</xref>), E/A (tricuspid) ratio (r=-0.333; p=0.016), pulmonary acceleration time (r=0.328; p=0.018), and lateral long axis amplitude (r=0.283; p=0.04) (<xref ref-type="table" rid="tab03-body2">Table 3</xref>). The dimensions of aorta, left atrium, interventricular septal thickness, E wave, A wave, E/A ratio, deceleration time of E wave, E (tricuspid) wave, A (tricuspid) wave, E (tricuspid) /A (tricuspid) ratio, deceleration time of E (tricuspid) and LV septal long axis amplitude had no significant correlation with 6-MWT (<xref ref-type="table" rid="tab03-body2">Table 3</xref>). </p>
      <table-wrap id="tab02-body2">
        <graphic xlink:href="1678-4170-abc-92-02-0127-00009-gt02-en.jpg"/></table-wrap>
      <fig id="fig02-body2">
        <graphic xlink:href="1678-4170-abc-92-02-0127-00009-gf02-en.jpg"/></fig>
      <fig id="fig03-body2">
        <graphic xlink:href="1678-4170-abc-92-02-0127-00009-gf03-en.jpg"/></fig>
      <fig id="fig04-body2">
        <graphic xlink:href="1678-4170-abc-92-02-0127-00009-gf04-en.jpg"/></fig>
      <table-wrap id="tab03-body2">
        <graphic xlink:href="1678-4170-abc-92-02-0127-00009-gt03-en.jpg"/></table-wrap>
      <p>Multivariate analysis was performed using linear regression model. Results of this model (<xref ref-type="table" rid="tab04-body2">Table 4</xref>) demonstrated that age, restrictive transmitral filling pattern and left ventricular end-systolic dimension were independent factors that influence the 6-MWT. All these parameters were inversely related to the 6-MWT. Age of the patients emerged as the strongest independent predictive factor, followed by restrictive filling pattern and left ventricular end- systolic dimension.</p>
      <table-wrap id="tab04-body2">
        <graphic xlink:href="1678-4170-abc-92-02-0127-00009-gt04-en.jpg"/></table-wrap>
      <p>
        <bold>Discussion</bold>
      </p>
      <p>To our knowledge, this is the first study to correlate 6-MWT performance in patients with chronic heart failure. The main finding of our study is that the 6-MWT has a moderate, but statistically significant correlation with LV systolic dimension, global LV systolic function parameters, LV MPI, as well as with long axis systolic function of left and right ventricles in patients with chronic stable heart failure due to LV systolic dysfunction. </p>
      <p>Another finding of our study was that age, restrictive transmitral filling pattern, and left ventricular systolic dimension are independently related to the 6-MWT in stable chronic heart failure patients due to left ventricular systolic dysfunction, without rheumatic valvular heart disease. </p>
      <p>Heart failure is an epidemiological entity that is increasing worldwide, and now represents a major health problem in most developed countries<sup>1</sup>. The measurement of quality of life in heart failure patients has proved more elusive than what was anticipated. It is still unclear which one is better for the assessment of grading of heart failure: if the judgment of the physician, the use of the NYHA classification or the use of many sophisticated questionnaires. </p>
      <p>The 6-MWT was originally used by physicians to assess patients with lung disease<sup>32,33</sup>, and later was introduced as an alternative objective measure of submaximal exercise capacity of congestive heart failure patients<sup>11</sup>. Previous studies show controversial results about the correlation of 6-MWT with functional exercise capacity in chronic heart failure patients. The 6-min walk test was shown to be correlated with peak oxygen uptake in dilated cardiomyopathy and to have a predictive value in these patients<sup>34-36</sup>. The 6-MWT was also shown to be a useful prognostic marker in these patients<sup>26,27,37</sup>. However, Opasich et al<sup>38</sup> demonstrated that in moderate to severe chronic heart failure patients, the 6-min walk test is not related to cardiac function and only moderately related to exercise capacity.</p>
      <p>It was also proven that the 6-MWT distance was improved after a follow-up in patients with LV systolic dysfunction that received ACE-inhibitors<sup>39,40</sup>, new-generation beta-blockers<sup>18-22</sup>, and underwent exercise training<sup>23</sup>. </p>
      <p>There are several clinical implications that could be suggested from this study. Several important echocardiographic parameters are independently related to 6-MWT and therefore can be used to predict the quality of life of the patients. Age emerged as an independent factor inversely related to 6-MWT. Therefore, independently from echocardiographic results, the quality of life deteriorates with age probably due to complex factors associated with aging.</p>
      <p>The small number of patients could be mentioned as a limitation of this study, especially for the comprehensive multivariate analysis.</p>
      <p>In conclusion, in patients with heart failure due to left ventricular systolic dysfunction, the 6-MWT as a clinical assessment tool of the functional capacity has a significant correlation with the most important global LV systolic function parameters, as well as with LV MPI. In patients with LV systolic dysfunction, age, restrictive transmitral filling pattern, and left ventricular systolic dimension, were independently associated with the 6-MWT.</p>
      <p>
        <bold>Potential Conflict of Interest</bold>
      </p>
      <p>No potential conflict of interest relevant to this article was reported.</p>
      <p>
        <bold>Sources of Funding</bold>
      </p>
      <p>There were no external funding sources for this study.</p>
      <p>
        <bold>Study Association</bold>
      </p>
      <p>This study is not associated with any post-graduation program.</p>
      <p>
        <bold>References</bold>
      </p>
    </body>
  </sub-article>
  <sub-article article-type="translation" id="TRes" xml:lang="es">
    <front-stub>
      <article-categories/>
      <title-group>
        <article-title xml:lang="es">Ecocardiograf&#237;a y prueba de caminata de 6 minutos en la disfunci&#243;n sist&#243;lica del ventr&#237;culo izquierdo</article-title>
      </title-group>
      <abstract xml:lang="es">
        <p>FUNDAMENTO: La insuficiencia cardiaca cr&#243;nica es un grave disturbio cardiovascular. OBJETIVO: El objetivo de este estudio fue evaluar prospectivamente si el resultado de la prueba de caminata de 6 minutos (PC-6M) se correlaciona con las variables ecocardiogr&#225;ficas en pacientes portadores de disfunci&#243;n sist&#243;lica del ventr&#237;culo izquierdo e insuficiencia cardiaca cr&#243;nica estable. M&#201;TODOS: Se estudiaron prospectivamente a 52 pacientes (el 65% varones; promedio de edad de 60&#177;11 a&#241;os) portadores de insuficiencia cardiaca cr&#243;nica secundaria a la cardiopat&#237;a isqu&#233;mica o la miocardiopat&#237;a idiop&#225;tica. Todos los pacientes presentaban disfunci&#243;n sist&#243;lica del ventr&#237;culo izquierdo (fracci&#243;n de eyecci&#243;n &lt;0.45) y se encontraban en insuficiencia cardiaca clase funcional II &#243; III de la NYHA. Se realizaron un estudio de Ecocardiograf&#237;a Doppler y una PC-6M en el mismo d&#237;a. RESULTADOS: La PC-6M present&#243; correlaci&#243;n moderada, pero estad&#237;sticamente significante, con el di&#225;metro sist&#243;lico final (DSF): r=-0,46; p=0,0006; con la fracci&#243;n de acortamiento (FA): r=0,52; p=0,0001; y con la fracci&#243;n de eyecci&#243;n (FE): r=0,5; p=0,0001. Present&#243; tambi&#233;n correlaci&#243;n d&#233;bil, pero estad&#237;sticamente significante, con el &#237;ndice de desempe&#241;o mioc&#225;rdico (IDM): r=-0,39; p=0,0046; la relaci&#243;n E/A (tric&#250;spide): r=-0,333; p=0,016; el tiempo de aceleraci&#243;n del flujo pulmonar: r=0,328; p=0,018; y con la amplitud del eje largo lateral: r=0,283; p=0,04. El modelo de regresi&#243;n lineal evidenci&#243; que la edad (&#967;2=-0,59, p=&lt;0,001), el patr&#243;n de llenado restrictivo transmitral (&#967;2=-0,44, p=0,004) y la dimensi&#243;n sist&#243;lica final del ventr&#237;culo izquierdo (&#967;2=-0,34, p=0,012) fueron factores independientes que influencian la PC-6M. CONCLUSIONES: En pacientes portadores de insuficiencia cardiaca resultante de disfunci&#243;n sist&#243;lica del ventr&#237;culo izquierdo, la PC-6M como herramienta de evaluaci&#243;n cl&#237;nica de la capacidad funcional presenta una correlaci&#243;n significante con los principales par&#225;metros de la funci&#243;n sist&#243;lica global del VI y con el IDM del VI. En pacientes con disfunci&#243;n sist&#243;lica del VI, la edad, el patr&#243;n de llenado restrictivo transmitral y la dimensi&#243;n sist&#243;lica del ventr&#237;culo izquierdo se mostraron independientemente asociados a la PC-6M.</p>
      </abstract>
      <kwd-group xml:lang="es">
        <kwd>Insuficiencia cardiaca</kwd>
        <kwd>ecocardiograf&#237;a</kwd>
        <kwd>caminata</kwd>
        <kwd>calidad de vida</kwd>
      </kwd-group>
    </front-stub>
    <body>
      <p>
        <bold>ART&#205;CULO ORIGINAL</bold>
      </p>
      <p>
        <fn id="tx-body3">
          <label>
            <bold>Ecocardiograf&#237;a y prueba de caminata de 6 minutos en la disfunci&#243;n sist&#243;lica del ventr&#237;culo izquierdo</bold>
          </label>
          <p>
            <bold>Venera Berisha<sup>I</sup>; Gani Bajraktari<sup>I</sup>; Dritero Dobra<sup>II</sup>; Edmond Haliti<sup>I</sup>; Reshat Bajrami<sup>I</sup>; Shpend Elezi<sup>II</sup></bold>
          </p>
        </fn>
      </p>
      <p><sup>I</sup>Segunda Divisi&#243;n de Cardiolog&#237;a &#150; Cl&#237;nica General &#150; Universidad Centro Cl&#237;nico de Kosova</p>
      <p><sup>II</sup>Prishtina, Kosovo; Facultad de Medicina, Universidad de Prishtina, Prishtina - Kosovo</p>
      <p>Correspondencia</p>
      <p>
        <bold>RESUMEN</bold>
      </p>
      <p><bold>FUNDAMENTO:</bold> La insuficiencia cardiaca cr&#243;nica es un grave disturbio cardiovascular.</p>
      <p><bold>OBJETIVO:</bold> El objetivo de este estudio fue evaluar prospectivamente si el resultado de la prueba de caminata de 6 minutos (PC-6M) se correlaciona con las variables ecocardiogr&#225;ficas en pacientes portadores de disfunci&#243;n sist&#243;lica del ventr&#237;culo izquierdo e insuficiencia cardiaca cr&#243;nica estable.</p>
      <p><bold>M&#201;TODOS:</bold> Se estudiaron prospectivamente a 52 pacientes (el 65% varones; promedio de edad de 60&#177;11 a&#241;os) portadores de insuficiencia cardiaca cr&#243;nica secundaria a la cardiopat&#237;a isqu&#233;mica o la miocardiopat&#237;a idiop&#225;tica. Todos los pacientes presentaban disfunci&#243;n sist&#243;lica del ventr&#237;culo izquierdo (fracci&#243;n de eyecci&#243;n <underline>&lt;</underline>0.45) y se encontraban en insuficiencia cardiaca clase funcional II &#243; III de la NYHA. Se realizaron un estudio de Ecocardiograf&#237;a Doppler y una PC-6M en el mismo d&#237;a.</p>
      <p><bold>RESULTADOS:</bold> La PC-6M present&#243; correlaci&#243;n moderada, pero estad&#237;sticamente significante, con el di&#225;metro sist&#243;lico final (DSF): r=-0,46; p=0,0006; con la fracci&#243;n de acortamiento (FA): r=0,52; p=0,0001; y con la fracci&#243;n de eyecci&#243;n (FE): r=0,5; p=0,0001. Present&#243; tambi&#233;n correlaci&#243;n d&#233;bil, pero estad&#237;sticamente significante, con el &#237;ndice de desempe&#241;o mioc&#225;rdico (IDM): r=-0,39; p=0,0046; la relaci&#243;n E/A (tric&#250;spide): r=-0,333; p=0,016; el tiempo de aceleraci&#243;n del flujo pulmonar: r=0,328; p=0,018; y con la amplitud del eje largo lateral: r=0,283; p=0,04. El modelo de regresi&#243;n lineal evidenci&#243; que la edad (&#967;<sup>2</sup>=-0,59, p=&lt;0,001), el patr&#243;n de llenado restrictivo transmitral (&#967;<sup>2</sup>=-0,44, p=0,004) y la dimensi&#243;n sist&#243;lica final del ventr&#237;culo izquierdo (&#967;<sup>2</sup>=-0,34, p=0,012) fueron factores independientes que influencian la PC-6M.</p>
      <p><bold>CONCLUSIONES:</bold> En pacientes portadores de insuficiencia cardiaca resultante de disfunci&#243;n sist&#243;lica del ventr&#237;culo izquierdo, la PC-6M como herramienta de evaluaci&#243;n cl&#237;nica de la capacidad funcional presenta una correlaci&#243;n significante con los principales par&#225;metros de la funci&#243;n sist&#243;lica global del VI y con el IDM del VI. En pacientes con disfunci&#243;n sist&#243;lica del VI, la edad, el patr&#243;n de llenado restrictivo transmitral y la dimensi&#243;n sist&#243;lica del ventr&#237;culo izquierdo se mostraron independientemente asociados a la PC-6M.</p>
      <p><bold>Palabras clave:</bold> Insuficiencia cardiaca, ecocardiograf&#237;a, caminata, calidad de vida.</p>
      <p>
        <bold>Introducci&#243;n</bold>
      </p>
      <p>La insuficiencia cardiaca cr&#243;nica es una de las principales enfermedades cardiovasculares, y su incidencia y prevalencia son crecientes<sup>1</sup>. La ecocardiograf&#237;a bidimensional con Doppler es un m&#233;todo sensible y no invasivo de detecci&#243;n de anormalidades cardiacas y disfunci&#243;n sist&#243;lica y/o diast&#243;lica<sup>2</sup>. Las variables de llenado diast&#243;lico permiten la identificaci&#243;n posterior de subgrupos con pron&#243;sticos de largo plazo divergentes<sup>3</sup>. Recientemente, se sugiri&#243; el &#237;ndice de desempe&#241;o mioc&#225;rdico (IDM) para evaluar la funci&#243;n ventricular<sup>4</sup>. Se calcula el IDM desde los registros del Doppler pulsado de las velocidades de entrada y salida de los ventr&#237;culos y, por lo tanto, combina el desempe&#241;o ventricular sist&#243;lico y diast&#243;lico. Dicho &#237;ndice expresa la funci&#243;n ventricular global y es menos afectado por anormalidades segmentares localizadas de la movilidad de la pared, adem&#225;s de desempe&#241;ar un rol pron&#243;stico importante en el diagn&#243;stico de insuficiencia cardiaca<sup>5</sup> y en la previsi&#243;n de eventos cardiacos en pacientes con infarto agudo de miocardio<sup>6</sup>. Generalmente, se grad&#250;a la gravedad de la insuficiencia cardiaca congestiva de acuerdo con los s&#237;ntomas de los pacientes, particularmente con las actividades f&#237;sicas que inducen disnea o fatiga. La clasificaci&#243;n funcional de insuficiencia cardiaca de la NYHA satisface s&#243;lo algunos de esos criterios. Sin embargo, esa clasificaci&#243;n se basa en la autoevaluaci&#243;n del paciente y su confiabilidad es a&#250;n discutible<sup>7</sup>. El instrumento ideal para la estratificaci&#243;n de riesgo y establecimiento de la mejor conducta cl&#237;nica para los pacientes portadores de insuficiencia cardiaca congestiva debe ser objetivo, simple, barato y seguro. La captaci&#243;n m&#225;xima de ox&#237;geno, medida durante la prueba de esfuerzo cardiopulmonar, es un par&#225;metro m&#225;s objetivo para evaluar la capacidad funcional y predecir la supervivencia en pacientes con insuficiencia cardiaca<sup>8-10</sup>. No obstante, ese m&#233;todo est&#225; restricto s&#243;lo a los centros especializados, porque requiere un equipo sofisticado y un personal espec&#237;ficamente entrenado.</p>
      <p>Se propuso la prueba de caminata de 6 minutos (PC-6M) como una t&#233;cnica alternativa simple y precisa para la medici&#243;n de la capacidad subm&#225;xima de esfuerzo en pacientes portadores de insuficiencia cardiaca congestiva<sup>11</sup>. Se toma en consideraci&#243;n que ello est&#233; realmente relacionado a la actividad f&#237;sica diaria. Por consiguiente, se lo incorpor&#243; no s&#243;lo a estudios de evaluaci&#243;n de la capacidad de esfuerzo<sup>12,13</sup> y de calidad de vida<sup>14</sup>, sino tambi&#233;n a estudios de eficacia de nuevos agentes terap&#233;uticos<sup>15-17</sup> incluy&#233;ndose betabloqueantes<sup>18-22</sup>, y de programas de entrenamiento f&#237;sico<sup>23</sup> y de estratificaci&#243;n pron&#243;stica<sup>24-29</sup>.</p>
      <p>El objetivo del presente estudio fue evaluar la relaci&#243;n entre los par&#225;metros del ecocardiograma bidimensional con Doppler y la PC-6M en pacientes con insuficiencia cardiaca y disfunci&#243;n sist&#243;lica del ventr&#237;culo izquierdo. Se utiliza la PC-6M como una medida indirecta de la calidad de vida. Por tanto, par&#225;metros ecocardiogr&#225;ficos que presentan asociaci&#243;n independiente con la PC-6M facilitar&#237;an la previsi&#243;n de la calidad de vida.</p>
      <p>
        <bold>M&#233;todos</bold>
      </p>
      <p>
        <bold>Poblaci&#243;n del estudio</bold>
      </p>
      <p>El grupo del estudio incluy&#243; a 52 pacientes portadores de insuficiencia cardiaca cr&#243;nica estable secundaria a la cardiopat&#237;a isqu&#233;mica o la miocardiopat&#237;a idiop&#225;tica, que ingresaron a la Segunda Divisi&#243;n de Cardiolog&#237;a de la Cl&#237;nica General de la Universidad Centro Cl&#237;nico de Kosova, en Prishtina, Kosovo, entre diciembre de 2005 y abril de 2007.</p>
      <p>El promedio de edad fue de 60&#177;11 a&#241;os. La etiolog&#237;a de la insuficiencia cardiaca fue miocardiopat&#237;a dilatada idiop&#225;tica en 19 pacientes y miocardiopat&#237;a isqu&#233;mica en 33 individuos. Todos los pacientes presentaban aumento del ventr&#237;culo izquierdo (dimensi&#243;n diast&#243;lica del ventr&#237;culo izquierdo [VI] &gt;5,7cm) y disfunci&#243;n sist&#243;lica global del ventr&#237;culo izquierdo (fracci&#243;n de eyecci&#243;n del ventr&#237;culo izquierdo [FEVI] &lt;0,45), y todos se encontraban en insuficiencia cardiaca estable clase funcional II o III de <italic>New York Heart Association</italic> (NYHA). La capacidad funcional fue clase II en 27 pacientes y clase III en los 25 restantes. Las caracter&#237;sticas cl&#237;nicas y laboratoriales de los pacientes est&#225;n presentadas en la <xref ref-type="table" rid="tab01-body3">Tabla 1</xref>.</p>
      <table-wrap id="tab01-body3">
        <graphic xlink:href="1678-4170-abc-92-02-0127-00009-gt01-es.jpg"/></table-wrap>
      <p>Se excluyeron del estudio a los pacientes con disturbio de ritmo (fibrilaci&#243;n atrial, arritmias ventriculares graves), los que presentaban insuficiencia cardiaca descompensada, limitaci&#243;n de la actividad f&#237;sica debido a otros factores que no la disnea de esfuerzo y la fatiga (por ejemplo, artritis), y los portadores de insuficiencia renal de moderada a grave, con enfermedad pulmonar obstructiva cr&#243;nica. Se excluyeron asimismo a los pacientes que hab&#237;an presentado angina inestable, infarto agudo de miocardio o accidente cerebrovascular, anemia y cualesquiera enfermedades febriles o infecciosas.</p>
      <p>El estudio fue aprobado por el Comit&#233; de &#201;tica de la instituci&#243;n y todos los pacientes firmaron el formulario de consentimiento informado. El tratamiento cl&#237;nico est&#225;ndar con, por ejemplo, inhibidores de la ECA, betabloqueantes, digoxina y diur&#233;ticos se lo optimiz&#243; de modo individual, tom&#225;ndose como base los s&#237;ntomas y la funci&#243;n renal dos semanas antes de la prueba ergom&#233;trica como m&#237;nimo. Todos los pacientes siguieron recibiendo la medicaci&#243;n de rutina cuando de la realizaci&#243;n del ecocardiograma y de la PC-6M.</p>
      <p>
        <bold>Recolecci&#243;n de datos</bold>
      </p>
      <p>Se obtuvo la historia cl&#237;nica de todos los individuos y se realizaron los ex&#225;menes f&#237;sico y bioqu&#237;micos de rutina: conteo de hemat&#237;es, leucocitos, hemoglobina, hematocrito, velocidad de sedimentaci&#243;n de hemat&#237;es (VHS), urea, creatinina, glicemia, colesterol, triglic&#233;ridos, y marcadores inflamatorios (fibrin&#243;geno, prote&#237;na C reactiva [PCR]). Se midieron el peso, la estatura, la cintura y la cadera.</p>
      <p>
        <bold>Ex&#225;menes ecocardiogr&#225;ficos</bold>
      </p>
      <p>Se realiz&#243; el examen ecocardiogr&#225;fico por medio del ecocardi&#243;grafo Philips Intelligent E-33 con transductor multifrecuencia e imagen harm&#243;nica, seg&#250;n conviniera. Todos los ecocardiogramas fueron realizados por el mismo investigador. Se efectu&#243; el estudio ecocardiogr&#225;fico en dec&#250;bito lateral izquierdo, en las proyecciones del eje largo paraesternal y de cuatro c&#225;maras.</p>
      <p>Los registros transversales unidimensionales, guiados bidimensionalmente desde el eje corto del VI, se los realizaron mediante la proyecci&#243;n del eje largo paraesternal izquierdo, con el cursor en las puntas de los velos de la v&#225;lvula mitral. Se calcul&#243; la fracci&#243;n de acortamiento como el descenso del porcentaje en la dimensi&#243;n de la cavidad del VI durante la s&#237;stole en comparaci&#243;n con la del final de la di&#225;stole. La fracci&#243;n de eyecci&#243;n del ventr&#237;culo izquierdo se estim&#243; a trav&#233;s del m&#233;todo biplano de Simpson. La dimensi&#243;n del atrio izquierdo se midi&#243; con base en los registros de ultrasonido unidimensional con el cursor cruzando la ra&#237;z a&#243;rtica al nivel de los velos de la v&#225;lvula a&#243;rtica. Los registros en modo unidimensional del eje largo del VI se obtuvieron con el cursor posicionado en los &#225;ngulos lateral y septal del anillo mitral, y los del eje largo del ventr&#237;culo derecho con el cursor posicionado en el &#225;ngulo lateral del anillo tric&#250;spide. Todos los registros en modo unidimensional se obtuvieron con aproximaci&#243;n para que las im&#225;genes fueran mejores y, de esa manera, las medidas m&#225;s exactas. </p>
      <p>La funci&#243;n diast&#243;lica de los ventr&#237;culos derecho e izquierdo se evalu&#243; por Doppler pulsado. El volumen de muestra del Doppler pulsado fue posicionado en las puntas de los velos mitral y tric&#250;spide, respectivamente. Se registraron las ondas E y A, con base en las cuales se calcul&#243; la relaci&#243;n E/A, adem&#225;s del tiempo de desaceleraci&#243;n de la onda E (TD-E). Asimismo se registraron la onda Er, la onda Ar y la relaci&#243;n Er/Ar.</p>
      <p>El IDM se midi&#243; desde los intervalos de tiempo de la velocidad del flujo de entrada mitral y el flujo de salida del VI, de acuerdo con lo descrito por Tei et al.<sup>30</sup>. El intervalo <italic>a </italic>medido desde el t&#233;rmino hasta el inicio del flujo de entrada mitral es igual al total del tiempo de contracci&#243;n isovolum&#233;trica (TCI), tiempo de eyecci&#243;n (TE) y tiempo de relajaci&#243;n isovolum&#233;trica (TRI). El tiempo de eyecci&#243;n del ventr&#237;culo izquierdo <italic>b </italic>es la duraci&#243;n del perfil de velocidad del flujo de salida del ventr&#237;culo izquierdo. De ese modo, la suma del TCI y del TRI se obtuvo al sustraerse <italic>b </italic>de a. El &#237;ndice combinado de la funci&#243;n sist&#243;lica y diast&#243;lica (suma de TCI y TRI dividida por el tiempo de eyecci&#243;n) se calcul&#243; como (<italic>a</italic> &#150; <italic>b</italic>) / <italic>b</italic> (<xref ref-type="fig" rid="fig01-body3">Figura 1</xref>). El TRI se pudo medirlo sustray&#233;ndose el intervalo <italic>d</italic>, entre la onda R y el final del flujo de salida del VI, del intervalo <italic>c</italic>, entre la onda R y el inicio del flujo de entrada mitral. El TCI se calcul&#243; sustray&#233;ndose el TRI de <italic>a-b.</italic></p>
      <fig id="fig01-body3">
        <graphic xlink:href="1678-4170-abc-92-02-0127-00009-gf01-es.jpg"/></fig>
      <p>La gravedad de la insuficiencia mitral se evalu&#243; por medio de Doppler color y Doppler continuo y se la clasific&#243; como leve, moderada o severa, de acuerdo con la distancia del chorro desde el orificio de la v&#225;lvula y del perfil de velocidad del flujo, respectivamente, conforme a lo recomendado por la Sociedad Americana de Ecocardiograf&#237;a<sup>31</sup>. De igual manera, se evalu&#243; la insuficiencia tric&#250;spide a trav&#233;s de Doppler color y Doppler continuo, desde la proyecci&#243;n apical de cuatro c&#225;maras. Un descenso en la presi&#243;n transvalvular tric&#250;spide retr&#243;grada &gt; 35 mmHg se consider&#243; como una se&#241;al de hipertensi&#243;n pulmonar cuando no hab&#237;a dilataci&#243;n del atrio derecho.</p>
      <p>
        <bold>Prueba de caminata de 6 minutos</bold>
      </p>
      <p>Tras las 24 horas de la realizaci&#243;n del ecocardiograma, se realiz&#243; una PC-6M en un pasillo llano. La prueba fue aplicada por una enfermera que desconoc&#237;a los resultados del ecocardiograma. De acuerdo con el m&#233;todo de Gyatt et al.<sup>11,12</sup>, todos los pacientes se informaron del objetivo, m&#233;todos y utilizaci&#243;n de los resultados de la prueba de caminata de 6 minutos. La PC-6M se realiz&#243; de acuerdo con un protocolo estandarizado, entre las 10h y las 16h, luego de la medicaci&#243;n habitual<sup>11</sup>. Se utiliz&#243; un pasillo llano de 15 m, libre de obst&#225;culos, con sillas posicionadas en cada una de sus extremidades. Los pacientes fueron orientados a caminar la mayor distancia posible, volvi&#233;ndose 180&#186; a cada 15m, dentro del l&#237;mite de tiempo de seis minutos. Los pacientes caminaron solos para que no hubiera influencia sobre la velocidad de la caminata y fueron solicitados a caminar la mayor distancia posible durante seis minutos. Los pacientes podr&#237;an descansarse, si hubiera necesidad, y el tiempo remanente les era informado a cada dos minutos. Al final de los seis minutos, el m&#233;dico midi&#243; la distancia total recorrida por el paciente.</p>
      <p>
        <bold>An&#225;lisis estad&#237;stico</bold>
      </p>
      <p>Los datos se presentaron como promedio &#177; DE o proporciones (% de pacientes). Los datos continuos se compararon por medio de la prueba t de Student a dos colas no pareada. Los datos discretos se compararon a trav&#233;s de la prueba Chi-cuadrado. La correlaci&#243;n entre variables se realiz&#243; a trav&#233;s de la prueba de correlaci&#243;n de Pearson. Valores de p &lt; 0.05 se consideraron estad&#237;sticamente significantes. Se realiz&#243; el an&#225;lisis multivariado por medio del modelo de regresi&#243;n lineal. Los factores incluidos en ese modelo fueron los que siguen: edad, patr&#243;n de llenado restrictivo transmitral, dimensi&#243;n sist&#243;lica del ventr&#237;culo izquierdo, &#237;ndice de desempe&#241;o mioc&#225;rdico y diabetes mellitus.</p>
      <p>
        <bold>Resultados</bold>
      </p>
      <p>Las caracter&#237;sticas cl&#237;nicas y laboratoriales de los 52 pacientes incluidos en el estudio est&#225;n presentadas en la <xref ref-type="table" rid="tab01-body3">Tabla 1</xref>, y las medidas ecocardiogr&#225;ficas y de Doppler, en la <xref ref-type="table" rid="tab02-body3">Tabla 2</xref>. Hubo una correlaci&#243;n moderada, pero estad&#237;sticamente significante entre la PC-6M el espesor de la pared posterior del VI (r= 0,49; p&lt;0,001), dimensi&#243;n sist&#243;lica final del ventr&#237;culo izquierdo (r=0,46, p&lt;0,001, <xref ref-type="fig" rid="fig02-body3">Fig. 2</xref>); fracci&#243;n de acortamiento del VI (r = 0,517, p&lt;0,001, <xref ref-type="fig" rid="fig03-body3">Fig. 3</xref>) y FEVI (r = 0,50, p&lt;0,001); al paso que hubo una correlaci&#243;n d&#233;bil, pero estad&#237;sticamente significante con el &#237;ndice de desempe&#241;o mioc&#225;rdico (IDM) (r=-0,39; p=0,0046, <xref ref-type="fig" rid="fig04-body3">Fig. 4</xref>); relaci&#243;n E/A (tric&#250;spide) (r=-0,333; p=0,016); tiempo de aceleraci&#243;n del flujo pulmonar (r=0,328; p=0,018) y amplitud del eje largo lateral (r=0,283; p=0,04) (<xref ref-type="table" rid="tab03-body3">Tabla 3</xref>). Las dimensiones de la aorta, atrio derecho, espesor del septo interventricular, onda E, onda A, relaci&#243;n E/A, tiempo de desaceleraci&#243;n de la onda E, onda E (tric&#250;spide), onda A (tric&#250;spide), relaci&#243;n E (tric&#250;spide)/A (tric&#250;spide), tiempo de desaceleraci&#243;n de E (tric&#250;spide) y amplitud del eje largo del septo del VI no presentaron correlaci&#243;n significante con la PC-6M (<xref ref-type="table" rid="tab03-body3">Tabla 3</xref>).</p>
      <table-wrap id="tab02-body3">
        <graphic xlink:href="1678-4170-abc-92-02-0127-00009-gt02-es.jpg"/></table-wrap>
      <table-wrap id="tab03-body3">
        <graphic xlink:href="1678-4170-abc-92-02-0127-00009-gt03-es.jpg"/></table-wrap>
      <fig id="fig02-body3">
        <graphic xlink:href="1678-4170-abc-92-02-0127-00009-gf02-es.jpg"/></fig>
      <fig id="fig03-body3">
        <graphic xlink:href="1678-4170-abc-92-02-0127-00009-gf03-es.jpg"/></fig>
      <fig id="fig04-body3">
        <graphic xlink:href="1678-4170-abc-92-02-0127-00009-gf04-es.jpg"/></fig>
      <p>Se realiz&#243; el an&#225;lisis multivariado por medio del modelo de regresi&#243;n lineal. Los resultados de ese modelo (<xref ref-type="table" rid="tab04-body3">Tabla 4</xref>) evidenciaron que la edad, el patr&#243;n de llenado restrictivo transmitral y la dimensi&#243;n sist&#243;lica final del ventr&#237;culo izquierdo fueron factores independientes que influenciaron la PC-6M. Todos esos par&#225;metros se mostraron inversamente relacionados con la PC-6M. La edad de los pacientes surgi&#243; como el m&#225;s fuerte factor predictivo independiente, seguido por el patr&#243;n de llenado restrictivo y la dimensi&#243;n sist&#243;lica final del ventr&#237;culo izquierdo.</p>
      <table-wrap id="tab04-body3">
        <graphic xlink:href="1678-4170-abc-92-02-0127-00009-gt04-es.jpg"/></table-wrap>
      <p>
        <bold>Discusi&#243;n</bold>
      </p>
      <p>Hasta donde sabemos, este es el primer estudio a correlacionar el desempe&#241;o de la PC-6M en pacientes portadores de insuficiencia cardiaca cr&#243;nica. El principal hallazgo de nuestro estudio fue que la PC-6M presenta una moderada, pero estad&#237;sticamente significante correlaci&#243;n con la dimensi&#243;n sist&#243;lica del VI, con par&#225;metros de la funci&#243;n sist&#243;lica global del VI e IDM del VI, as&#237; como con la funci&#243;n sist&#243;lica de los ventr&#237;culos derecho e izquierdo en el eje largo en pacientes portadores de insuficiencia cardiaca cr&#243;nica estable resultante de disfunci&#243;n sist&#243;lica del VI. </p>
      <p>Otro hallazgo de nuestro estudio fue que la edad, el patr&#243;n de llenado restrictivo transmitral y la dimensi&#243;n sist&#243;lica del ventr&#237;culo izquierdo se encuentran independientemente relacionados con la PC-6M en pacientes portadores de insuficiencia cardiaca cr&#243;nica estable resultante de disfunci&#243;n sist&#243;lica del ventr&#237;culo izquierdo sin enfermedad valvular reum&#225;tica asociada.</p>
      <p>La insuficiencia cardiaca es una entidad epidemiol&#243;gica que est&#225; creciendo en el mundo todo, y hoy representa un problema de salud importante en la mayor&#237;a de los pa&#237;ses desarrollados<sup>1</sup>. La medida de la calidad de vida en portadores de insuficiencia cardiaca se ha presentado m&#225;s equivocada comparada a lo que se imaginaba anteriormente. Todav&#237;a no est&#225; claro lo que es mejor para la evaluaci&#243;n de la graduaci&#243;n de la insuficiencia cardiaca: si es el juicio del m&#233;dico, el uso de la clasificaci&#243;n funcional de NYHA, o si es el uso de diferentes cuestionarios sofisticados.</p>
      <p>La PC-6M fue originalmente utilizada por m&#233;dicos para evaluarse pneumopatas<sup>32,33</sup>, y posteriormente se la introdujo como una medida objetiva alternativa a la capacidad de esfuerzo subm&#225;xima de pacientes portadores de insuficiencia cardiaca congestiva<sup>11</sup>. Estudios anteriores evidencian resultados controvertidos sobre la correlaci&#243;n de la PC-6M con la capacidad de esfuerzo funcional en portadores de insuficiencia cardiaca cr&#243;nica. Se evidenci&#243; que la PC-6M se correlacion&#243; con la captaci&#243;n m&#225;xima de ox&#237;geno en la miocardiopat&#237;a dilatada y tiene un valor predictivo en esos pacientes<sup>34-36</sup>. La PC-6M tambi&#233;n se present&#243; como un marcador pron&#243;stico &#250;til en esos pacientes<sup>26,27,37</sup>. Sin embargo, Opasich et al<sup>38</sup> demostraron que la prueba de caminata de seis minutos no est&#225; relacionada a la funci&#243;n cardiaca, sino que est&#225; solamente relacionada de manera moderada con la capacidad de esfuerzo en portadores de insuficiencia cardiaca cr&#243;nica de moderada a severa.</p>
      <p>Tambi&#233;n se evidenci&#243; que la distancia recorrida en la PC-6M mejor&#243; tras el seguimiento de pacientes con disfunci&#243;n sist&#243;lica del VI que recibieron inhibidores de ECA<sup>39,40</sup>, betabloqueantes de nueva generaci&#243;n<sup>18-22</sup> y que se sometieron a entrenamiento f&#237;sico<sup>23</sup>.</p>
      <p>Hay varias implicaciones cl&#237;nicas que se podr&#237;an sugerir al tomarse en consideraci&#243;n este estudio. Varios par&#225;metros ecocardiogr&#225;ficos importantes se muestran independientemente relacionados a la PC-6M e, por lo tanto, se pueden utilizar para preverse la calidad de vida de los pacientes. La edad apareci&#243; como un factor independiente inversamente relacionado a la PC-6M. Por lo tanto, independientemente de los resultados de la ecocardiograf&#237;a, la calidad de vida se deteriora con la edad probablemente debido a factores complejos asociados al envejecimiento.</p>
      <p>El peque&#241;o n&#250;mero de pacientes se podr&#237;a establecer como una limitaci&#243;n de este estudio, espec&#237;ficamente a causa del abarcador an&#225;lisis multivariado.</p>
      <p>Entonces, se concluye que en pacientes portadores de insuficiencia cardiaca decurrente de disfunci&#243;n sist&#243;lica del ventr&#237;culo izquierdo, la PC-6M como herramienta de evaluaci&#243;n cl&#237;nica de la capacidad funcional presenta una correlaci&#243;n significante con los principales par&#225;metros de la funci&#243;n sist&#243;lica global del VI, as&#237; como con el IDM del VI. En pacientes con disfunci&#243;n sist&#243;lica del VI, la edad, el patr&#243;n de llenado restrictivo transmitral y la dimensi&#243;n sist&#243;lica del ventr&#237;culo izquierdo se mostraron independientemente asociados a la PC-6M.</p>
      <p>
        <bold>Referencias</bold>
      </p>
    </body>
  </sub-article>
</article>
